SiRNA for simultaneously inhibiting expression of two target genes, medicine and application of siRNA and medicine
By designing dual-targeting siRNA agents and combining them with the GalNAc system to target the AGT, PCSK9, and ANGPTL3 genes, the problem of insufficient in vivo stability and delivery efficiency of multi-target siRNA drugs in existing technologies has been solved, achieving effective treatment for hypertension, hyperlipidemia, and hypercholesterolemia.
Patent Information
- Application Number
- CN202411229643.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-06-13
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-03
AI Technical Summary
Existing technologies struggle to effectively suppress the expression of multiple target genes simultaneously, particularly AGT, PCSK9, and ANGPTL3 genes. This leads to complex treatments and poor adherence for chronic diseases such as hypertension, hyperlipidemia, and hypercholesterolemia. Furthermore, existing siRNA drugs suffer from insufficient stability and delivery efficiency in vivo.
The dual-targeting siRNA agent was designed to bind to hepatocyte-specific receptors via the GalNAc system, delivering siRNAs targeting AGT, PCSK9, and ANGPTL3. Nucleotide modifications were used to improve stability and activity, ensuring that different siRNAs do not antagonize each other, thus achieving sustained inhibition of both targets.
It achieves effective simultaneous inhibition of AGT, PCSK9 and ANGPTL3 genes, improves the duration of efficacy and safety in the treatment of hypertension, hyperlipidemia and hypercholesterolemia, and enhances the stability and activity of siRNA in vivo.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_4
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine, and in particular relates to siRNA, a drug and application thereof for simultaneously inhibiting the expression of two target genes. Background Art
[0002] Chronic diseases such as hypertension, hyperlipidemia, and hypercholesterolemia are the main causes of cardiovascular and cerebrovascular complications. With the improvement of human living standards, these chronic diseases have become important factors that plague people's health and reduce the quality of life. In most hypertension guidelines, systolic blood pressure (SBP) or diastolic blood pressure (DBP) ≥ 140 / 90 mmHg is defined as hypertension without the use of antihypertensive drugs (Whelton, Paul K et al. Hypertension vol. 71, 6 (2018): 1269-1324.). Hypertension usually occurs with other chronic diseases such as hyperlipidemia, high cholesterol, diabetes, etc. In a study involving 4942 outpatients with hypertension in 2009, 24.3% of them also had diabetes. In the above survey, the prevalence of hypertriglyceridemia was 18.9%, and the prevalence of hypercholesterolemia and low HDL cholesterol was 13.5% and 16.6%, respectively. The simultaneous occurrence of these diseases not only increases the risk of cardiovascular and cerebrovascular complications, but also complicates the management of such diseases (Miao, Chao-Ying et al. Journal of clinical hypertension vol. 23, 7 (2021): 1399-1404). It has been reported that antihypertensive treatment is beneficial to improve various indicators of patients, such as the risk of cardiovascular disease is reduced by 20% for every 10 mmHg reduction in systolic blood pressure; in addition, the risks of coronary heart disease, stroke, and heart function loss are reduced by 17%, 27%, and 28%, respectively. Due to the same risk factors and pathogenesis, the combination of antihypertensive and lipid-lowering drugs will have a synergistic effect on the treatment of the above-mentioned chronic diseases, and the improvement of cardiovascular and cerebrovascular diseases can also be used as an endpoint indicator for the treatment of hypertension (Ranasinghe, Priyanga et al. Journal of the American Heart Association vol. 11, 20 (2022): e027694.).
[0003] The renin-angiotensin-aldosterone system (RAAS) is an endocrine system that maintains blood pressure, blood volume and water-salt balance in the human body. The angiotensin (ANG I / II) secreted by this system has the effect of constricting blood vessels. Overactivation of the RAAS system is one of the important causes of hypertension (Arendse, Lauren B et al. Pharmacological reviews vol. 71, 4 (2019): 539-570). At present, the main antihypertensive drugs in clinical practice are RAAS inhibitors, including angiotensin-converting enzyme inhibitors ACEI (such as pril drugs), angiotensin II antagonists ARB (such as sartan drugs), etc. Even though the mechanism of action of these RAAS inhibitor drugs is not exactly the same, they have certain body compensation and require patients to take medication every day without interruption, so some patients have poor compliance. It is worth noting that angiotensinogen (AGT) produced by liver cells is the only precursor of angiotensin (Ang II). Studies have shown that the polymorphism of the AGT gene is closely related to the body's blood pressure regulation, so AGT is an important target for gene silencing treatment of hypertension and related diseases. Inhibiting AGT can effectively prevent the over-activation of the RAAS system, thereby playing a role in lowering blood pressure, making up for the common shortcomings of RAAS inhibitor drugs (Ren, Liwei et al. Current opinion in nephrology and hypertension vol. 29, 2 (2020): 180-189). Recent studies have shown that siRNA-mediated AGT gene silencing using a GalNAc system coupled to specific hepatocytes can inhibit the RAAS system for weeks to months, requiring only a single dose, which can improve compliance and cardiovascular and cerebrovascular diseases better than current RAAS inhibitors (Desai, Akshay S et al. The New England journal of medicine vol. 389, 3 (2023): 228-238.).
[0004] As mentioned above, hypertension is closely related to hyperlipidemia. Hyperlipidemia is usually caused by increased cholesterol and (or) triglyceride levels in serum, which is an important predisposing factor for cardiovascular diseases such as atherosclerosis. Loss-of-function mutations in the angiopoietin-like protein 3 (ANGPTL3) gene are associated with reduced plasma levels of triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol. Human genetic studies have shown that people carrying heterozygous ANGPTL3 loss-of-function mutations have significantly lower serum levels of triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein (LDL-C) cholesterol than those without these mutations (Dewey, Frederick E et al. The New England journal of medicine vol. 377, 3 (2017): 211-221.). In terms of function, ANGPTL3 produced by hepatocytes will be secreted into the blood and formed into active molecules after cleavage by PCSK3 or PCSK6, which can inhibit lipoprotein lipase (which catalyzes the hydrolysis of triglycerides) and endothelial lipase (which hydrolyzes lipoprotein phospholipids), thereby leading to increased plasma levels of triglycerides, high-density lipoprotein (HDL) and phospholipids. Therefore, inhibiting the expression of ANGPTL3 can be used as an important target for the treatment of hyperlipidemia (Kersten, Sander. Nature reviews. Endocrinology vol. 13, 12 (2017): 731-739.).
[0005] In addition, the proportion of hypercholesterolemia in patients with hypertension is also high, and hypercholesterolemia is generally defined based on LDL-C and non-HDL-C levels. Similarly, human genetic studies have shown that prealbumin convertase subtilisin / kexin type 9 (PCSK9) may be associated with familial hypercholesterolemia, and two common PCSK9 loss-of-function mutations (PCSK9-679X and PCSK9-142X) are positively correlated with low LDL-C levels in the blood (Cohen, Jonathan C et al. The New England journal of medicine vol. 354, 12 (2006): 1264-72.). PCSK9 is synthesized in the liver and secreted into the circulatory system. PCSK9 in cells can bind to and guide newly generated LDL receptors to be transported from the Golgi apparatus to the lysosome for degradation; and PCSK9 in the circulatory system can specifically bind to LDL receptors on the surface of liver cells, thereby mediating their entry into the lysosomes of liver cells for degradation, ultimately leading to a decrease in the liver's ability to bind and clear LDL-C and an increase in the level of LDL-C in the blood (Horton, Jay D et al. Journal of lipid research vol. 50 Suppl, Suppl (2009): S172-7). Therefore, inhibiting the expression level of PCSK9 is an important target for treating hypercholesterolemia and preventing cardiovascular and cerebrovascular diseases related to LDL-C. Currently, monoclonal antibody drugs, antisense oligonucleotide drugs (ASOs), siRNAs drugs, etc. targeting ANGPTL3 and PCSK9 have been developed for lipid-lowering treatments, and good therapeutic effects have been achieved using LDL-C or triglycerides as indicators (Chen, Ruoyu et al. Journal of clinical laboratory analysis vol. 36, 7 (2022): e24552.).
[0006] The discovery of the RNAi phenomenon has pushed RNA therapy to a new height. RNAi technology refers to the use of exogenous siRNAs to degrade the targeted target gene using the endogenous system of the cell. In terms of mechanism, the double-stranded siRNAs introduced exogenously can be recognized by the endoribonuclease Dicer in the cell and divided into a single-stranded guide strand and its complementary strand in the RNA-induced silencing complex (RISC). The siRNA as a guide strand then binds to the Argonate2 protein (AGO2) and guides it to the target RNA, and the degradation of the target RNA is mediated by AGO2. In addition to degrading RNAs in the cytoplasm, siRNAs can also promote chromosome remodeling and histone modification in the nucleus, thereby leading to transcriptional silencing (Matzke et al. Nature reviews. Genetics vol. 6, 1 (2005): 24-35.). At present, a variety of siRNA drugs have been approved by the FDA, and there are also many candidate siRNAs undergoing Phase III clinical trials (Zhu, Yiran et al. Cell death & disease vol. 13, 7644. 23 Jul. 2022). siRNA is unstable in blood and tissues, and is easily digested and degraded by nucleases in the body. In order to improve the stability of siRNA antisense and sense chains, chemical modifications such as 2'-O-methylation and 2'-fluoro modification are usually introduced when synthesizing siRNA drugs. The delivery of siRNA drugs is also an important guarantee for RNAi treatment. The most mature delivery system at present is N-oligosaccharide acetylgalactosamine (GalNAc), which can be combined with asialoglycoprotein receptors (ASGPR) specifically expressed by hepatocytes. After coupling with siRNA, it can realize active delivery of liver cells, which is an important breakthrough in the field of RNA therapy. The three genes AGT, ANGPTL3 and PCSK9 that the present invention is concerned about are all hepatocyte-specific or highly expressed proteins, so the liver delivery of single-target or dual-target siRNA drugs can be achieved using the GalNAc system (Debacker, Alexandre J et al. Molecular therapy vol. 28, 8 (2020): 1759-1771).
[0007] At present, RNAi drugs targeting the PSCK9 gene have been approved for marketing, while RNAi drugs targeting the AGT and ANGPTL3 genes are still in the research and development stage, and both have shown good therapeutic effects. However, it is still of great significance to further develop highly effective RNAi drugs with long-lasting efficacy. Dual-target RNAi drugs formed by combining siRNAs targeting the three genes have great clinical application prospects for the combined treatment of chronic cardiovascular and cerebrovascular diseases such as hypertension, hyperlipidemia, and hypercholesterolemia. For example, the combination of siRNAs of AGT and ANGPTL3, AGT and PSCK9 into dual-target drugs may have a synergistic therapeutic effect on lowering blood pressure and lowering blood lipids; and the combination of siRNAs of ANGPTL3 and PSCK9 into dual-target drugs may achieve unexpected drug efficacy persistence for the treatment of hypercholesterolemia or hyperlipidemia, thereby improving the therapeutic effect. However, there are not many siRNAs that are truly suitable for clinical applications with single targets, and it is even more difficult to use different siRNAs targeting two target genes at the same time. In addition to effectively controlling the target gene, the two siRNAs must not antagonize each other in vivo, and the duration of the two targets must be roughly consistent. However, due to the huge prospects for medical applications, research on multiple targets is still welcomed and expected. Summary of the invention
[0008] Based on this, the purpose of the present invention is to provide a dual-targeted siRNA agent for simultaneously inhibiting the expression of any two target genes of angiotensinogen (AGT), proprotein convertase subtilisin / kexin type 9 (PCSK9) and angiopoietin-like 3 (ANGPTL3) in cells and its application, which has the advantages of being able to effectively inhibit the expression of two target genes in vivo at the same time, without mutual antagonism, high activity and high safety.
[0009] In a first aspect of the present invention, a dual-targeting siRNA agent is provided, wherein the dual-targeting siRNA agent comprises two different siRNAs or pharmaceutically acceptable salts thereof targeting two different genes, wherein the two different siRNAs or their salts are connected to a ligand for nucleic acid delivery to form a whole, wherein the siRNA is a dsRNA consisting of a sense strand and an antisense strand, and the two different genes are selected from two of AGT, PCSK9 and ANGPTL3;
[0010] The base composition of the siRNA targeting AGT is selected from one of the following dsRNA sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide:
[0011] A) the dsRNA duplex is 1167f, wherein the sense strand comprises UGACCAGCUUGUUUGUGAA (SEQ ID NO: 59), and the antisense strand comprises UUCACAAACAAGCUGGUCGGG (SEQ ID NO: 60);
[0012] B) the dsRNA duplex is 1167b, wherein the sense strand comprises GCCGACCAGCUUGUUUGUGAA (SEQ ID NO: 51), and the antisense strand comprises UUCACAAACAAGCUGGUCGGC (SEQ ID NO: 52);
[0013] C) the dsRNA duplex is 1165d, wherein the sense strand comprises GAGAACCAGUGUUUAGCGA (SEQ ID NO: 39), and; the antisense strand comprises UCGCUAAACACUGGUUCUUGG (SEQ ID NO: 40);
[0014] D) the dsRNA duplex is 1165f, wherein the sense strand comprises CCAAGAACCAGUGUUUAGCGA (SEQ ID NO: 43), and the antisense strand comprises UCGCUAAACACUGGUUCUUGG (SEQ ID NO: 44);
[0015] The base composition of the siRNA targeting PCSK9 is selected from one of the following dsRNA sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide:
[0016] E) the dsRNA duplex is 11040a, wherein the sense strand comprises CUUAUUCUGGGUUUUGUAGCA (SEQ ID NO: 375), and the antisense strand comprises UGCUACAAAACCCAGAAUAAG (SEQ ID NO: 376);
[0017] F) the dsRNA duplex is 11002d, wherein the sense strand comprises GCAGCCAACUUUUCUAGAA (SEQ ID NO: 259), and the antisense strand comprises UUCUAGAAAAGUUGGCUGUGG (SEQ ID NO: 260);
[0018] G) the dsRNA duplex is 11002a, wherein the sense strand comprises CUACAGCCAACUUUUCUAGAA (SEQ ID NO: 253), and the antisense strand comprises UUCUAGAAAAGUUGGCUGUAG (SEQ ID NO: 254);
[0019] The base composition of the siRNA targeting ANGPTL3 is selected from one of the following dsRNA sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide:
[0020] H) the dsRNA duplex is 7061f, wherein the sense strand comprises UACUUGAACUCAACUCAAA (SEQ ID NO: 579), and the antisense strand comprises UUUGAGUUGAGUUCAAGUGGG (SEQ ID NO: 580); I) the dsRNA duplex is 7061b, wherein the sense strand comprises GCCACUUGAACUCAACUCAAA (SEQ ID NO: 571), and the antisense strand comprises UUUGAGUUGAGUUCAAGUGGC (SEQ ID NO: 572).
[0021] In some embodiments, the dual-targeted siRNA agent targets genes AGT and PCSK9, AGT and ANGPTL3, and PCSK9 and ANGPTL3.
[0022] In some embodiments, the targeted gene is AGT and any one selected from PCSK9 and ANGPTL3, preferably AGT and PCSK9.
[0023] The present invention also provides a method for modifying the nucleotides used in the above siRNA, which is used to improve the stability and activity of the siRNA in vivo and in vitro and to reduce the non-target activity. The modified nucleotides include at least 2'-O-methyl modified nucleotides, 2'-fluorine modified nucleotides, 2'-deoxy nucleotides, 2'3'-seco nucleotide mimetics, LNA, open ring nucleic acid nucleotides (UNA), glycol nucleic acid nucleotides (GNA), 2'-F-arabinose nucleotides, 2'-methoxyethyl nucleotides, abasic nucleotides, ribitol, reverse nucleotides, reverse abasic residues, reverse 2'-OMe nucleotides, reverse 2'-deoxy nucleotides, 2'-amino modified nucleotides, 2'-alkyl modified nucleotides, morpholino nucleotides and 3'-OMe nucleotides, nucleotides containing 5'-phosphorothioate groups, or terminal nucleotides connected to cholesterol derivatives or dodecanoic acid bisdecylamide groups, 2'-amino modified nucleotides, phosphoramidates, or non-natural bases containing nucleotides, etc. One or more of the following.
[0024] In some of the embodiments, the sense strand comprises no more than 3, 2, 1 or 0 unmodified nucleotides, the modified nucleotides in the sense strand comprise 2'-O-methyl modified nucleotides, 2'-deoxy nucleotides, 2'-fluoro modified nucleotides, inverted abasic residues, and the sense strand contains 0, or 1, or 2, or 3 thiophosphate bonds at the 5'-end and the 3'-end; and wherein the antisense strand comprises no more than 3, 2, 1 or 0 unmodified nucleotides, the modified nucleotides in the antisense strand comprise 2'-O-methyl modified nucleotides, 2'-deoxy nucleotides, 2'-fluoro modified nucleotides, VPU (2'-O-methyluridine-5'-(E)-vinyl phosphate-3'-phosphate), VPU-S (2'-S-methyluridine-5'-(E)-vinyl phosphate-3'-phosphate) or other VPU derivatives, and the antisense strand contains 1-3 thiophosphate bonds at the 5'-end and the 3'-end.
[0025] In some embodiments, the dsRNA duplex targeting the AGT gene is modified and selected from one of the following sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide:
[0026] a) The dsRNA duplex is 1167.25-19, wherein the 5'-3' sense strand comprises
[0027] I nvab*mU*mGmAmCmCmAfGfCfUfUmGfUmUmUmGmUmGmAmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fU*mCmAmCmAmAmAmCmAmAdGmCfUmGfGmUmCmG*mG*mG;
[0028] b) The dsRNA duplex is 1167.27-21, wherein the 5'-3' sense strand comprises
[0029] I nvab*mG*mCmCmGmAmCmCmAfGfCfUfUmGfUmUmUmGmUmGmAmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fU*mCmAmCmAmAmAmCmAmAdGmCfUmGfGmUmCmG*mG*mC;
[0030] c) The dsRNA duplex is 1165.5-14, wherein the 5'-3' sense strand comprises
[0031] I nvab*mG*mAmGmAmAmCfCfAfGfUmGfUmUmUmAmGmCmGmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fC*mGmCmUmAmAmAmCmAmCdTmGfGmUfUmCmUmU*mG*mG;
[0032] d) The dsRNA duplex is 1165.5-16, wherein the 5'-3' sense strand comprises
[0033] I nvab*mC*mCmAmAmGmAmAmCfCfAfGfUmGfUmUmUmAmGmCmGmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fC*mGmCmUmAmAmAmCmAmCdTmGfGmUfUmCmUmU*mG*mG.
[0034] In some embodiments, the siRNA targeting PCSK9 is modified and selected from one of the following sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide:
[0035] e) The dsRNA duplex is 11040.10-23, wherein the 5'-3' sense strand comprises
[0036] I nvab*mC*mUmUmAmUmUmCmUfGfGfGfUmUfUmUmGmUmAmGmCmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fG*mCmUmAmCmAmAmAmAmCdCmCfAmGfAmAmUmA*mA*mG;
[0037] f) The dsRNA duplex is 11002.17-21, wherein the 5'-3' sense strand comprises
[0038] I nvab*mG*mCmAmGmCmCfAfAfCfUmUfUmUmCmUmAmGmAmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fU*mCmUmAmGmAmAmAmAmGdTmUfGmGfCmUmGmU*mG*mG;
[0039] g) The dsRNA duplex is 11002.10-23, wherein the 5'-3' sense strand comprises
[0040] I nvab*mC*mUmAmCmAmGmCmCfAfAfCfUmUfUmUmCmUmAmGmAmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fU*mCmUmAmGmAmAmAmAmGdTmUfGmGfCmUmGmU*mA*mG.
[0041] In some embodiments, the dsRNA targeting the ANGPTL3 gene is modified and selected from one of the following sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide:
[0042] h) The dsRNA is 7061.18-14, wherein the 5'-3' sense strand comprises
[0043] I nvab*mU*mAmCmUmUmGfAfAfCfUmCfAmAmCmUmCmAmAmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fU*mUmGmAmGmUmUmGmAmGdTmUfCmAfAmGmUmG*mG*mG;
[0044] i) The dsRNA duplex is 7061.4-16, wherein the 5'-3' sense strand comprises
[0045] I nvab*mG*mCmCmAmCmUmUmGfAfAfCfUmCfAmAmCmUmCmAmAmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fU*mUmGmAmGmUmUmGmAmGdTmUfCmAfAmGmUmG*mG*mC.
[0046] Wherein, the above VPU-S is 2'-S-methyluridine-5'-(E)-vinyl phosphate-3'-phosphate, mA is 2'-O-methyladenosine-3'-phosphate, mU is 2'-O-methyluridine-3'-phosphate, mC is 2'-O-methylcytidine-3'-phosphate, mG is 2'-O-methylguanosine-3'-phosphate, fA is 2'-fluoroadenosine-3'-phosphate, fU is 2'-fluorouridine-3'-phosphate, fC is 2'-fluorocytidine-3'-phosphate, fG is 2'-fluoroguanosine-3'-phosphate, dA is 2'-deoxyadenosine-3'-phosphate, dT is 2'-deoxythymidine-3'-phosphate, dC is 2'-deoxycytidine-3'-phosphate, dG is 2'-deoxyguanosine-3'-phosphate, I nvab is an inverted abasic residue, and * is a phosphorothioate bond.
[0047] In some embodiments, the ligand is N-acetylgalactosamine (GalNAc) or a derivative thereof.
[0048] In some embodiments, the N-acetylgalactosamine or its derivative is connected to the 3' end of the sense strands of the two siRNAs respectively through chemical bonds, preferably, through phosphate bonds or phosphorothioate bonds.
[0049] In some embodiments, the structure of the ligand is as follows:
[0050]
[0051] In some of these embodiments, the ligand is linked to the 3' end of the sense strand of the siRNA.
[0052] In some embodiments, the ligand is linked to the 3' end of the sense strand of the siRNA as follows:
[0053]
[0054] Represents siRNAs targeting modified sequences of AGT, PCSK9, or ANGPTL3.
[0055] In some of these embodiments, when targeting AGT and PCSK9 genes, each siRNA of the dual-targeted siRNA agent is selected from the sequence shown in any one of DT03081, DT03086, DT03103, DT03099, DT03085, DT03101, DT03082, DT03097, DT03100 or DT03102 in Table 45.
[0056] In some of these embodiments, when targeting AGT and ANGPTL3 genes, each siRNA of the dual-targeting siRNA agent is selected from the sequence shown in any one of DT02043 or DT02047 in Table 45.
[0057] In some of these embodiments, when targeting ANGPTL3 and PCSK9 genes, each siRNA of the dual-targeting siRNA agent is selected from the sequence shown in any one of DT09001, DT09003 and DT09005 in Table 45.
[0058] The second aspect of the present invention provides the use of any of the above dual-targeting siRNA agents in the preparation of a double-stranded siRNA product that simultaneously inhibits the expression of two target sites (target genes) of any combination of AGT, PCSK9 and ANGPTL3.
[0059] In some embodiments, the product is a biological preparation or a pharmaceutical preparation.
[0060] The third aspect of the present invention is to provide the use of any of the above dual-targeted siRNA agents in the preparation of drugs for preventing and / or treating hypertension and / or lipid disorder-related diseases.
[0061] The fourth aspect of the present invention is to provide a biological preparation or a pharmaceutical preparation for simultaneously inhibiting the expression of two target genes in any combination of AGT, PCSK9 and ANGPTL3, wherein the active ingredient includes any of the above-mentioned dual-target siRNA agents.
[0062] A fifth aspect of the present invention is to provide a method for simultaneously inhibiting the expression of any combination of two target genes among AGT, PCSK9 and ANGPTL3, the method comprising:
[0063] (a) contacting cells in vivo or in vitro with any of the above-mentioned corresponding dual-targeting siRNA agents or the above-mentioned biological agents or pharmaceutical agents; and
[0064] (b) maintaining the cells produced in step (a) for a time sufficient to obtain degradation of mRNA transcripts expressed by any combination of two targets of AGT, PCSK9 and ANGPTL3, thereby simultaneously inhibiting the expression of any combination of two targets of AGT, PCSK9 and ANGPTL3 in the cells.
[0065] A method for treating a disease associated with AGT gene and / or PCSK9 gene and / or ANGPTL3 gene, comprising administering a therapeutically effective amount of the above-mentioned dual-targeting siRNA agent or the above-mentioned biological agent or pharmaceutical agent to the subject, thereby treating the subject.
[0066] In some embodiments, the cell is in vivo or in vitro in a subject. Preferably, the subject is a mammal.
[0067] In some of these embodiments, the subject is a human.
[0068] In some embodiments, the expression of AGT, PCSK9 and ANGPTL3 is inhibited by at least about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98% or about 100%.
[0069] Among them, the hypertension diseases are mediated by the AGT gene, including but not limited to critical hypertension, primary hypertension, secondary hypertension, hypertensive crisis, hypertensive emergency state, isolated systolic and diastolic hypertension, pregnancy-related hypertension, diabetic hypertension, resistant hypertension, intractable hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt's hypertension, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension and unstable hypertension or other diseases mediated by the AGT gene.
[0070] The lipid disorder diseases are mediated by the PCSK9 gene, including but not limited to hyperlipidemia, atherosclerosis, non-alcoholic fatty hepatitis, non-alcoholic fatty liver disease or other diseases mediated by the PCSK9 gene.
[0071] Among them, the lipid disorder diseases are mediated by the ANGPTL3 gene, including but not limited to hyperlipidemia, hypertriglyceridemia, lipid and / or cholesterol metabolism disorders, homozygous and heterozygous familial hypercholesterolemia, statin-resistant hypercholesterolemia, cardiometabolic diseases, obesity, atherosclerosis, type II diabetes, cardiovascular disease, coronary artery disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, pancreatitis caused by hypertriglyceridemia or other diseases mediated by the ANGPTL3 gene.
[0072] The sixth aspect of the present invention is to provide a siRNA targeting the AGT gene, PCSK9 gene or ANGPTL3 gene, which can be used as a single-target drug or a dual-target drug.
[0073] An siRNA targeting the AGT gene or a pharmaceutically acceptable salt thereof, wherein the sequence is selected from one of the following, or a sense strand or antisense strand sequence that differs therefrom by no more than 1 nucleotide:
[0074] A) the dsRNA is 1167f, wherein the sense strand comprises UGACCAGCUUGUUUGUGAA (SEQ ID NO: 59), and the antisense strand comprises UUCACAAACAAGCUGGUCGGG (SEQ ID NO: 60);
[0075] B) the dsRNA is 1167b, wherein the sense strand comprises GCCGACCAGCUUGUUUGUGAA (SEQ ID NO: 51), and the antisense strand comprises UUCACAAACAAGCUGGUCGGC (SEQ ID NO: 52);
[0076] C) the dsRNA is 1165d, wherein the sense strand comprises GAGAACCAGUGUUUAGCGA (SEQ ID NO: 39), and the antisense strand comprises UCGCUAAACACUGGUUCUUGG (SEQ ID NO: 40);
[0077] D) the dsRNA is 1165f, wherein the sense strand comprises CCAAGAACCAGUGUUUAGCGA (SEQ ID NO: 43), and the antisense strand comprises UCGCUAAACACUGGUUCUUGG (SEQ ID NO: 44);
[0078] In some embodiments, the siRNA is modified and selected from one of the following sequences, or a sense strand or antisense strand sequence that differs therefrom by no more than 1 nucleotide:
[0079] a) The dsRNA is 1167.25-19, wherein the 5'-3' sense strand comprises
[0080] I nvab*mU*mGmAmCmCmAfGfCfUfUmGfUmUmUmGmUmGmAmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fU*mCmAmCmAmAmAmCmAmAdGmCfUmGfGmUmCmG*mG*mG;
[0081] b) The dsRNA is 1167.27-21, wherein the 5'-3' sense strand comprises
[0082] I nvab*mG*mCmCmGmAmCmCmAfGfCfUfUmGfUmUmUmGmUmGmAmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fU*mCmAmCmAmAmAmCmAmAdGmCfUmGfGmUmCmG*mG*mC;
[0083] c) the dsRNA is 1165.5-14, wherein the 5'-3' sense strand comprises
[0084] I nvab*mG*mAmGmAmAmCfCfAfGfUmGfUmUmUmAmGmCmGmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fC*mGmCmUmAmAmAmCmAmCdTmGfGmUfUmCmUmU*mG*mG;
[0085] d) dsRNA is 1165.5-16, wherein the 5'-3' sense strand comprises
[0086] I nvab*mC*mCmAmAmGmAmAmCfCfAfGfUmGfUmUmUmAmGmCmGmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fC*mGmCmUmAmAmAmCmAmCdTmGfGmUfUmCmUmU*mG*mG;
[0087] A siRNA targeting the PCSK9 gene or a pharmaceutically acceptable salt thereof, wherein the sequence is selected from one of the following, or a sense strand or antisense strand sequence that differs therefrom by no more than 1 nucleotide:
[0088] E) the dsRNA is 11040a, wherein the sense strand comprises CUUAUUCUGGGUUUUGUAGCA (SEQ ID NO: 375), and the antisense strand comprises UGCUACAAAACCCAGAAUAAG (SEQ ID NO: 376);
[0089] F) the dsRNA is 11002d, wherein the sense strand comprises GCAGCCAACUUUUCUAGAA (SEQ ID NO: 259), and the antisense strand comprises UUCUAGAAAAGUUGGCUGUGG (SEQ ID NO: 260);
[0090] G) the dsRNA is 11002a, wherein the sense strand comprises CUACAGCCAACUUUUCUAGAA (SEQ ID NO: 253), and the antisense strand comprises UUCUAGAAAAGUUGGCUGUAG (SEQ ID NO: 254);
[0091] In some embodiments, the siRNA targeting the proprotein convertase subtilisin / kexin type 9 gene (PCSK9 gene) is modified and selected from one of the following sequences, or a sense strand or antisense strand sequence that differs therefrom by no more than 1 nucleotide:
[0092] e) The dsRNA is 11040.10-23, wherein the 5'-3' sense strand comprises
[0093] I nvab*mC*mUmUmAmUmUmCmUfGfGfGfUmUfUmUmGmUmAmGmCmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fG*mCmUmAmCmAmAmAmAmCdCmCfAmGfAmAmUmA*mA*mG;
[0094] f) The dsRNA is 11002.17-21, wherein the 5'-3' sense strand comprises
[0095] I nvab*mG*mCmAmGmCmCfAfAfCfUmUfUmUmCmUmAmGmAmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fU*mCmUmAmGmAmAmAmAmGdTmUfGmGfCmUmGmU*mG*mG;
[0096] g) The dsRNA is 11002.10-23, wherein the 5'-3' sense strand comprises
[0097] I nvab*mC*mUmAmCmAmGmCmCfAfAfCfUmUfUmUmCmUmAmGmAmAI nvab, and the 5'-3' antisense strand comprises VPU-S*fU*mCmUmAmGmAmAmAmAmGdTmUfGmGfCmUmGmU*mA*mG;
[0098] An siRNA targeting the ANGPTL3 gene or a pharmaceutically acceptable salt thereof, wherein the sequence is selected from one of the following, or a sense strand or antisense strand sequence that differs therefrom by no more than 1 nucleotide:
[0099] H) the dsRNA is 7061f, wherein the sense strand comprises UACUUGAACUCAACUCAAA (SEQ ID NO: 579), and the antisense strand comprises UUUGAGUUGAGUUCAAGUGGG (SEQ ID NO: 580);
[0100] I) the dsRNA is 7061b, wherein the sense strand comprises GCCACUUGAACUCAACUCAAA (SEQ ID NO: 571), and the antisense strand comprises UUUGAGUUGAGUUCAAGUGGC (SEQ ID NO: 572);
[0101] In some embodiments, the siRNA is modified and selected from one of the following sequences, or a sense strand or antisense strand sequence that differs therefrom by no more than 1 nucleotide:
[0102] h) The dsRNA is 7061.18-14, wherein the 5'-3' sense strand comprises
[0103] I nvab*mU*mAmCmUmUmGfAfAfCfUmCfAmAmCmUmCmAmAmAI nvab, and the antisense strand comprises VPU-S*fU*mUmGmAmGmUmUmGmAmGdTmUfCmAfAmGmUmG*mG*mG;
[0104] i) The dsRNA is 7061.4-16, wherein the 5'-3' sense strand comprises
[0105] I nvab*mG*mCmCmAmCmUmUmGfAfAfCfUmCfAmAmCmUmCmAmAmAI nvab, and the antisense strand comprises VPU-S*fU*mUmGmAmGmUmUmGmAmGdTmUfCmAfAmGmUmG*mG*mC;
[0106] The seventh aspect of the present invention is to provide a siRNA agent targeting the AGT gene, PCSK9 gene or ANGPTL3 gene, wherein the active ingredient comprises any one of the above-mentioned siRNAs or a pharmaceutically acceptable salt thereof connected to a ligand.
[0107] In some embodiments, the ligand is an N-acetylgalactosamine derivative, and preferably, the structural formula of the ligand is as follows:
[0108]
[0109] In some embodiments, the ligand is connected to the 3' end of the sense strand via a chemical bond, preferably, the chemical bond is a phosphate bond or a phosphorothioate bond, and the connection is as follows:
[0110]
[0111] or
[0112]
[0113] After studying siRNA sequences and conducting a large number of experiments, we have screened a number of dual-target siRNA agents that can be used to simultaneously inhibit the expression of two targets in any combination of AGT, PCSK9 and ANGPTL3. On this basis, appropriate modifications have been made to improve the silencing ability of the target and reduce non-target activity. It can be used for single targets and even more for dual targets. At the same time, the siRNA agent described in the present invention can be delivered to the liver simultaneously through a delivery system using a suitable and preferred combination of two targets to exert a better active effect. The invention is expected to be used clinically in the treatment of hypertension or / and lipid disorders related to two targets in any combination of AGT, PCSK9 and ANGPTL3. BRIEF DESCRIPTION OF THE DRAWINGS
[0114] Figure 1This is the curve showing the inhibitory effect of AGT / PCSK9 dual-targeting siRNA DT03081 on AGT target in AAV8-hAGT / hPCSK9 mice at a dose of 60 nmol / kg over time.
[0115] Figure 2 This is the curve showing the inhibitory effect of AGT / PCSK9 dual-targeting siRNA DT03081 on PCSK9 target in AAV8-hAGT / hPCSK9 mice at a dose of 60 nmol / kg over time. DETAILED DESCRIPTION
[0116] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.
[0117] The experimental methods in the following examples where specific conditions are not specified are generally carried out under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturers. The various commonly used chemical reagents used in the examples are all commercially available products.
[0118] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used in the present invention includes any and all combinations of one or more of the related listed items.
[0119] The present invention provides a dual-targeting siRNA agent, which comprises two different siRNAs targeting two different genes or pharmaceutically acceptable salts thereof, wherein the siRNA is a dsRNA consisting of a sense strand and an antisense strand, wherein the siRNA comprises a first dsRNA targeting a first gene and a second dsRNA targeting a second gene, wherein the first dsRNA and the second dsRNA are connected by a pharmaceutically acceptable ligand, and the first targeting gene and the second targeting gene are respectively selected from angiotensinogen (angiotensinogen, AGT), angiopoietin-like protein 3 (angiopoietin-like 3, ANGPTL3), and proprotein convertase subtilisin / kexin type 9 (PCSK9);
[0120] The expression of two targets of any combination of AGT, ANGPTL3 and PCSK9 can be evaluated based on the level of any variable related to the expression of AGT, ANGPTL3 and PCSK9 genes, such as the level of AGT, ANGPTL3 and PCSK9 mRNA in tissue or serum, the level of AGT, ANGPTL3 and PCSK9 protein, the level of related blood lipids, etc. Inhibition can be evaluated by a decrease in the absolute level or relative level of one or more of these variables compared to a control level. The control level can be any type of control level used in the art, such as a baseline level before administration, or a level measured from a similar subject, cell or sample that has not been treated or has been treated with a control, and a known population level.
[0121] In some of the embodiments, the disease associated with the expression of any combination of two targets such as AGT, ANGPTL3 and PCSK9 is hypertension and / or lipid disorder.
[0122] The use of the drug in the treatment and / or prevention of diseases related to hypertension, wherein the diseases related to hypertension are mediated by the AGT gene, including but not limited to critical hypertension, primary hypertension, secondary hypertension, hypertensive crisis, hypertensive emergency state, isolated systolic and diastolic hypertension, pregnancy-related hypertension, diabetic hypertension, refractory hypertension, intractable hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt's hypertension, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension and unstable hypertension or other diseases mediated by the AGT gene.
[0123] The use of the drug in the treatment and / or prevention of diseases related to lipid disorders, wherein the diseases related to lipid disorders are mediated by the PCSK9 gene, including but not limited to hyperlipidemia, atherosclerosis, non-alcoholic fatty hepatitis, non-alcoholic fatty liver disease or other diseases related to PCSK9 gene mediation.
[0124] The use of the drug in the treatment or / and prevention of lipid disorders, wherein the lipid disorders are mediated by the ANGPTL3 gene, including but not limited to hyperlipidemia, hypertriglyceridemia, lipid and / or cholesterol metabolism disorders, homozygous and heterozygous familial hypercholesterolemia, statin-resistant hypercholesterolemia, cardiometabolic diseases, obesity, atherosclerosis, type II diabetes, cardiovascular disease, coronary artery disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, pancreatitis caused by hypertriglyceridemia, or other diseases mediated by the ANGPTL3 gene.
[0125] Delivery of the siRNA agents of the invention to cells, such as cells in a subject (e.g., a human subject, such as a subject suffering from AGT, ANGPTL3, and PCSK9-related disorders such as hemochromatosis) can be achieved by a variety of different routes. For example, delivery can be performed by contacting the cells with the siRNA of the invention either in vitro or in vivo. In vivo delivery can also be performed by administering a composition comprising the siRNA or a salt thereof to a subject.
[0126] Generally, any method of delivering nucleic acid molecules (in vitro or in vivo) can refer to existing delivery technologies. For in vivo delivery, factors to be considered for the delivery of siRNA molecules include, for example, the biological stability of the delivered molecules, the prevention of non-specific effects, and the accumulation of the delivered molecules in the target tissue. The formulation can be administered locally (for example, by direct injection or implantation into a tissue or topical administration). Local administration to the treatment site maximizes the local concentration of the drug formulation, limits exposure of the agent to systemic tissues that can be damaged or degraded by the agent, and allows a lower total dose of siRNA molecules to be administered.
[0127] For systemic administration of siRNA to treat disease, the RNA can be modified or delivered using a drug delivery system; both methods act to prevent rapid degradation of dsRNA by endonucleases and exonucleases in vivo. Modifications to the RNA or pharmaceutical carriers can also allow the siRNA composition to be targeted to the target tissue and avoid off-target effects. siRNA molecules can be modified by chemically conjugating to lipophilic groups such as cholesterol, such as lipid particles, to enhance cellular uptake and prevent degradation.
[0128] The present invention also includes pharmaceutical compositions and preparations, which include any of the siRNA or salts thereof of the present invention. In some embodiments, the pharmaceutical preparation contains a pharmaceutical composition of the siRNA or salt thereof described herein and a pharmaceutically acceptable carrier. The pharmaceutical composition containing the siRNA is useful for treating diseases or conditions associated with AGT, ANGPTL3 and PCSK9, such as hemochromatosis. Such pharmaceutical compositions are formulated based on the delivery mode.
[0129] In some embodiments, the composition is formulated for systemic administration via parenteral delivery such as intravenous (IV) delivery or subcutaneous (SC) delivery. In the method of the present invention, the pharmaceutical preparation of the siRNA or its salt can be administered in a solution, preferably in a sterile solution, such as by injection.
[0130] In the present invention, "therapeutically effective amount" includes, when administered to a patient for the treatment of AGT, ANGPTL3 and PCSK9 related diseases, the amount of siRNA or its salt is sufficient to cause the treatment of the disease (e.g., by weakening, alleviating or maintaining the existing disease, or one or more symptoms of the disease). The "therapeutically effective amount" may vary depending on the pharmaceutical formulation of the siRNA or its salt, how the formulation is administered, the disease and its severity, and the patient's medical history, age, weight, family history, genetic composition, stage of the pathological process mediated by AGT, ANGPTL3 and PCSK9, etc., the type of previous treatment or combined treatment (if any), and other independent characteristics.
[0131] In the present invention, a "prophylactically effective amount" includes an amount of a pharmaceutical agent comprising siRNA or a salt thereof that is sufficient to prevent or alleviate the disease or one or more symptoms of the disease when administered to a subject who has not yet experienced or manifested symptoms of a disease related to AGT, ANGPTL3 and PCSK9 but may be susceptible to the disease. Alleviating the disease includes delaying the progression of the disease or reducing the severity of the disease that subsequently develops. The "prophylactically effective amount" may vary depending on how the pharmaceutical formulation of the siRNA or a salt thereof is administered, the degree of risk of the disease, and the patient's medical history, age, weight, family history, genetic makeup, stage of the pathological process mediated by AGT, ANGPTL3 and PCSK9 expression, type of previous treatment or combination therapy (if any), and other independent characteristics to be treated.
[0132] "Therapeutically effective amount" or "prophylactically effective amount" also includes an amount of siRNA at any reasonable benefit-risk ratio acceptable for treatment.
[0133] The targeted delivery ligand or other types of delivery carriers of the present invention, wherein the ligand is preferably an N-acetylgalactosamine derivative (GalNAc carrier), other types of delivery carriers such as liposomes that are specifically delivered to liver cells can be used in the present invention as long as they can achieve the delivery of siRNA.
[0134] In recent years, GalNAc carriers have been studied in depth. GalNAc-nucleic acid is a monoconjugate formed by a carbohydrate compound and a nucleic acid. N-acetylated galactosamine is covalently conjugated to the 3′ and / or 5′ end of the sense chain of RNA of different sequences in a trivalent state to form GalNAc-siRNA drugs, thereby achieving specific delivery to hepatocytes, and allowing the drug to enter the cells and exert its function through endocytosis.
[0135] All siRNAs in the present invention target human AGT, PCSK9 or ANGPTL3. In some embodiments, hAGT, hPCSK9 or hANGPTL3 are used to express the target in order to emphasize that the gene or protein detected in AAV8-transfected mice or humanized mice is human AGT, human PCSK9 or human ANGPTL3.
[0136] In some of the following examples, the dual-target GalNAc ligand structure is as follows:
[0137]
[0138]
[0139] The single-target GalNAc ligands are as follows:
[0140]
[0141] In some of the following examples, the structure of the dual-target GalNAc ligand after connecting to siRNA is as follows:
[0142]
[0143]
[0144] The structure of the single-target GalNAc ligand after connecting to siRNA is as follows:
[0145]
[0146]
[0147] In the nucleic acid sequence table of the present invention, the abbreviations and structures of the nucleotide monomers used are as follows:
[0148]
[0149]
[0150]
[0151] According to existing techniques, a person skilled in the art can determine that the pharmaceutically acceptable salt of the siRNA can be a sodium salt or a potassium salt, for example, a sodium salt produced during purification.
[0152] Human angiotensinogen (AGT) mRNA [NCBI Reference Sequence: NM_001384479.1].
[0153] Human proprotein convertase subtilisin / kexin type 9 gene (PCSK9) mRNA [NCBI reference sequence.
[0154] NM_174936.4】:
[0155] Human angiopoietin-like protein 3 (ANGPTL3) mRNA [NCBI Reference Sequence: NM_014495.4].
[0156] The present invention is further described in detail below with reference to specific embodiments.
[0157] Example 1 siRNA targeting human AGT (hAGT)
[0158] On the 12-channel nucleic acid synthesizer of Beijing Qingke Biotechnology Co., Ltd., 0.2-1 μmol of oligonucleotides were synthesized using a solid-phase oligonucleotide synthesis scheme. The siRNA sequence needed to be synthesized on a CPG pre-filled column, and GalNAc-coupled CPG or universal CPG was used as needed. Aminolysis reagents were added to the synthesized oligonucleotides and incubated at 45-80°C to separate the oligonucleotides from the solid phase carrier to free the oligonucleotides. Then, the crude oligonucleotides were precipitated with ethanol, and the supernatant was discarded by high-speed centrifugation. The crude oligonucleotides were obtained by repeating two times, and the precipitate was resuspended in DEPC water. The crude oligonucleotides were purified by ion pairing HPLC, and the collected products were dried to powder in a vacuum centrifugal dryer. The purified products were dissolved in DEPC water and analyzed by TOF LC-MS. The concentration of the oligonucleotides was determined, and the required volumes of equimolar sense and antisense chains were calculated. The equimolar sense and antisense chains were mixed evenly, and double strands were prepared by annealing method by heating at 95°C for 5 minutes and then naturally cooling to room temperature.
[0159] Table 1: Sense and antisense sequences of unmodified siRNA targeting AGT gene
[0160]
[0161]
[0162]
[0163]
[0164]
[0165]
[0166] Next, we modified the siRNA to improve its stability in vivo and in vitro, enhance its activity against the target, and reduce its activity against non-targets. Unless otherwise stated, L96 delivery was used for in vivo and in vitro screening of single-target sequences to more realistically reflect the effect of liver-targeted siRNA. The 3' end of the sense strand of siRNA was connected to L96.
[0167] Duplex 1000PM (AD-85481) is the fastest-progressing AGT-targeting drug, Zilebesiran, which is currently in Phase II clinical trials with patent number US11015201B2 and is used as a positive comparison sequence.
[0168] Table 2: Modified siRNA sequences targeting AGT gene
[0169]
[0170]
[0171]
[0172]
[0173]
[0174]
[0175]
[0176]
[0177]
[0178]
[0179] Example 2 In vitro screening of siRNA targeting AGT
[0180] Experimental method 1: In vitro screening of siRNA using liposome transfection in Hep3B cells
[0181] Cell culture and 96-well plate transfection: In vitro experiments were performed in Hep3B cells using MEM + 10% FBS + 1X penicillin-streptomycin + 1X non-essential amino acid culture medium. When the cell flattening area reached 80%, the cells were digested with trypsin and the cell density was determined using a Scepter automatic cell counter (Millipore, #PHCC00000). At the same time, siRNA, Opti-MEM and INTERFERin (Polyplus) were mixed in a 96-well plate and incubated at room temperature for 10 minutes. Then, complete culture medium containing Hep3B cells was added to each well, and the 96-well plate was incubated in an incubator at 37°C, 5% CO2 for 24 hours.
[0182] RNA extraction and reverse transcription in 96-well plates: Oligo d(T)25 Magnetic Beads reagent (NEB) was used to extract mRNA from cells in 96-well plates. The medium in the 96-well plates was aspirated, and the plates were washed once with DPBS. 100 μl of cell lysis solution was added to each well, and then 20 μl of beads were added. The plates were shaken on an oscillator. The lysate in the wells was aspirated. 100 μl of washing buffer A was added to each well, and the plates were placed on a magnetic separation rack after being blown. Washing buffer A was aspirated, and then 100 μl of washing buffer B was used to blow up the beads, and the beads were transferred to a new 96-well plate, placed on a magnetic separation rack, and washing buffer B was aspirated. Then 100 μl of low-salt buffer was used to blow up the beads and transferred to a 96-well PCR plate. The 96-well PCR plate was placed on a magnetic separation rack, and the low-salt buffer was aspirated. 10 μL of elution buffer was added to each well to blow up the beads, and the plates were incubated at 50°C for 2 minutes to elute the mRNA from the beads. Prepare the reverse transcription system using StarScript Pro one-tube de-genomic reverse transcription premix (genstar), dispense 5 μL into each well of the 96-well PCR, add 5 μL of the mRNA solution obtained in the previous step, mix well, centrifuge briefly, and seal the plate with a sealing film. 9) Incubate at 37°C for 3 minutes, 50°C for 50 minutes, and then 85°C for 2 minutes on the PCR instrument, cool to 4°C, and the reverse transcription is complete.
[0183] Real-time fluorescence quantitative PCR: After reverse transcription, place the 96-well plate on a magnetic separation rack until the beads are adsorbed to the bottom, remove the reverse reagent, add the prepared QPCR system to the 96-well PCR plate, seal the plate with a sealing film, and perform PCR on the StepOnePlus real-time PCR system (applied biosystems). The ΔΔCt method was used to analyze the data, and cells transfected with the negative control sequence at the same concentration were used for test standardization.
[0184] The sequence of negative control AD-1955 is as follows:
[0185] Sense strand: CUUACGCUGAGUACUUCGAdTdT (SEQ ID NO: 703)
[0186] Antisense strand: UCGAAGUACUCAGCGUAAGdTdT (SEQ ID NO: 704).
[0187] The primers for detecting AGT are as follows:
[0188] Forward primer: ATTCTGCACACCGAGCTGAA (SEQ ID NO: 705)
[0189] Reverse primer: TCAAGCTCAAAAAAAATGCTGTTC (SEQ ID NO: 706)
[0190] Probe: CTGCAAAAATTGAGCAATGACCGCATC (SEQ ID NO: 707) (reporter gene 5'FAM, quencher group 3'MGB)
[0191] Experimental method 2: In vitro screening was performed in primary hepatocytes of humanized AGT mice (purchased from Jicui Pharmaceutical) or mice infected with AAV8 virus simultaneously expressing human AGT (hAGT) and ANGPTL3 (h ANGPTL3).
[0192] Construction of AAV8-infected mice stably expressing both hAGT and hANGPTL3 (AAV8-hAGT / hANGPTL3 mice): 1x10 11 Titer ultra-purified recombinant AAV8-hAGT and 1x10 11 Mice were infected with titered ultra-purified recombinant AAV8-hANGPTL3 virus particles to obtain transgenic mice that stably expressed both hAGT and hANGPTL3.
[0193] Extraction of mouse primary hepatocytes: Mouse hepatocytes were extracted by collagenase digestion through the inferior vena cava perfusion method. The cells were filtered through a tissue cell filter (BIOLOGIX, 15-1070) to obtain mouse primary hepatocytes with good activity, which were resuspended in DMEM medium + 10% FBS + 1X penicillin-streptomycin, and the cell density was determined using a Scepter automatic cell counter.
[0194] The methods of siRNA transfection, RNA extraction, reverse transcription, and real-time fluorescence quantitative PCR were the same as those in method 1. The free uptake method was used to deliver siRNA without the need to add INTERFERin.
[0195] Table 3: Experimental results of 0.1 nM modified siRNA transfection in Hep3B cells by liposome
[0196]
[0197] We used Hep3B cells to screen the activity of some sequences targeting AGT. Table 3 shows that at a concentration of 0.1 nM, the activities of multiple sequences such as 1131.21-11, 1165.1-1, 1167.1-1, and 1172.1-1 were similar to or better than the positive reference.
[0198] Table 4: Experimental results of 1 nM modified siRNA delivered by L96 in primary hepatocytes of humanized AGT mice
[0199]
[0200]
[0201] We further used humanized AGT mouse primary hepatocytes to evaluate the in vitro activity of the modified siRNA. As can be seen from Table 4, when delivered via L96, the activities of multiple siRNAs such as 1131.21-11 and 1167.1-1 were better than the positive reference sequence.
[0202] Table 5: Experimental results of 0.1 nM modified siRNA delivery via L96 in AAV8-hAGT / hANGPTL3 mouse primary hepatocytes
[0203]
[0204]
[0205] From the experimental data in Table 5, we can find that the activity of multiple siRNAs such as 1165.4-13 and 1167.3-14 is better than the positive reference 1000PM at a concentration of 0.1nM and delivered by L96 in AAV8-hAGT / hANGPTL3 mouse primary hepatocytes. Moreover, we found that even if the seed region is the same, the activity of 1165.4-13 is better than that of 1165.2-3, and the activity of the 19 / 21 paired 1167.3-14 sequence is better than that of the 21 / 21 paired 1167.2-4, indicating that some changes in the ending bases of siRNA will also greatly affect the activity of the sequence. Next, we evaluated the sequences with better activity in the above-mentioned in vitro experiments in mice.
[0206] Example 3 Evaluation of the effect of preferred sequences on AGT protein expression in AAV8-hAGT mice
[0207] Experimental methods:
[0208] 1. Adenovirus integration of hAGT
[0209] By 1x1011 The mice were infected with ultra-purified recombinant AAV8 virus particles to obtain transgenic mice stably expressing hAGT.
[0210] 2. Experimental grouping and drug administration
[0211] 14 days after the mice were injected with the virus, blood was collected from the submandibular vein, left to stand at room temperature for 30 minutes, centrifuged at 1000×g for 10 minutes, and the supernatant serum was taken and stored in a -80 degree refrigerator. The serum samples were diluted 1000 times, and the expression of hAGT in mouse serum was detected by Human Angiotensinogen / AGT / SerpinA8 ELISA Kit (Lianke Bio, Cat. No.: EK1202–96). Based on the expression of hAGT, the mice were evenly divided into groups, with 4 mice in each group. siRNA was dissolved in PBS and the concentration was adjusted to 0.2 mg / kg. The mice were subcutaneously injected with siRNA solution at a dose of 1 mg / kg.
[0212] 3.ELISA test
[0213] After siRNA injection, blood was collected from the submandibular vein at regular intervals, allowed to stand at room temperature for 30 minutes, centrifuged at 1000×g for 10 minutes, and the supernatant serum was collected. After diluting 1000 times, the hAGT expression was detected by ELISA. AGT remaining amount (%) = hAGT protein concentration on day N / hAGT protein concentration on day 0*100%.
[0214] Table 6: Experimental results of the changes in hAGT protein expression levels over time after hAGT-targeted siRNA at a dose of 1 mg / kg was delivered into AAV8-hAGT mice via L96
[0215]
[0216]
[0217] NA means not detected
[0218] From Table 6, we can see that some sequences with good in vitro activity are not as good as the positive reference after entering the body. The activities of several siRNAs such as 1161.3-7, 1165.3-11, 1167.4-14, 1172.2-17 and 1172.9-28 are equivalent to or better than the positive reference 1000PM. Especially on the 56th day, it can be clearly seen that the hAGT protein expression level of the positive reference sequence 1000PM group has significantly rebounded, while the hAGT protein expression level of the 1165.3-11, 1167.4-14, 1172.2-17 and 1172.9-28 groups is still maintained below 50%. In addition, the AGT expression of 1161.3-7 remained only 24% on the 30th day, while that of 1161.3-11 remained 45.1% on the 30th day, indicating that the activity of the same naked sequence was significantly different after different modifications, further proving that the effect of modification on siRNA activity is extremely important.
[0219] Example 4 siRNA safety test
[0220] 400 mg / kg of siRNA was subcutaneously injected into 7-8 week old mice (Viton Liva) once every two weeks for 4 weeks, for a total of 3 injections. The control group of mice was subcutaneously injected with normal saline once every two weeks for 4 weeks, for a total of 3 injections, with 4-6 mice in each group. Serum was collected 24 hours after the last injection for the detection of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.
[0221] Table 7: Safety test results of siRNA targeting AGT
[0222] siRNA ALT(U / L) AST(U / L) Normal saline 42 135 1167.3-14 31 75 1172.2-17 221 219 1191.1-1 325 347
[0223] From Table 7 we can see that different siRNA sequences have different effects on the liver function of mice. 1167.3-14 has no effect on liver function in mice, while 1172.2-17 and 1191.1-1 have a great effect.
[0224] Example 5 Effects of different modifications on the activity and stability of the preferred sequence targeting AGT
[0225] The sequence activity method is shown in Example 2.
[0226] The experimental method for siRNA stability study is as follows:
[0227] The compound sequence to be tested was accurately diluted with DEPC water to a working concentration of 10 μM.
[0228] Preparation of liver homogenate: Weigh 200 mg of mouse liver, add 1 mL of potassium phosphate buffer solution and 5 magnetic beads, and homogenize three times in a grinder at 60 Hz, 30 s / time to obtain 200 mg / mL liver homogenate.
[0229] Preparation of 72h samples: Take 17μL of 10μM test compound / positive compound working solution, add 153μL of liver homogenate to mix, vortex for 30s, take 75μL of the compound and liver homogenate mixed solution into an EP tube, the number of parallel samples is 2, place it in a 37℃ incubator for 72h, and take out 50μL after incubation.
[0230] Preparation of 0h samples: Take 75μL of liver homogenate in an EP tube, with 2 parallel samples, and incubate in a 37℃ incubator for 72h. After incubation, take out 45μL of liver homogenate, add 5μL of 10μM test compound / positive compound, and mix well.
[0231] After incubation, 5 μL of 50 μg / ml internal standard was added to each tube of the sample, mixed, and then 100 μL of lysis buffer was added to each tube, vortexed for 30 s, and allowed to stand for 20 min.
[0232] After all samples were treated by appropriate pretreatment methods, the supernatant was taken for instrumental analysis. Subsequently, the relative residual rate (%) was calculated as follows: (72h compound content / 0h compound content) × 100%.
[0233] Next, we explored whether all sequences near 1167 have high activity, so we selected sequences with 1-2 nucleotides difference from 1167 near 1167 and evaluated their activity in primary hepatocytes of humanized AGT mice. The results are shown in Table 8.
[0234] Table 8: Experimental results of 1 nM modified siRNA delivery via L96 in mouse primary hepatocytes
[0235]
[0236] We found that the activity of sequences 1198.1-1, 1222.1-1, 1223.1-1, 1224.1-1 was much worse than that of 1167.3-5. We also found that even with the same seed region, 1167.3-5 with 19 / 21 pairing was much more active than 1167.2-4 and 1167.11-15 with 21 / 21 pairing.
[0237] We then explored the effects of different modifications on the activity of 1167. The results are shown in Table 9.
[0238] Table 9: Experimental results of different transfection methods using different concentrations of modified siRNA in different cells
[0239]
[0240] NA means not detected
[0241] For the preferred sequence 1167, different modified siRNAs were designed, and the activities of these sequences were compared in vitro by liposome transfection and free uptake in Hep3B cells, AAV8-hAGT / hPCSK9 mouse primary hepatocytes, and humanized AGT mouse primary hepatocytes. The experimental method refers to Example 2. As can be seen from Table 9, different modifications have a great influence on the activity of the sequence. The most active 1167.17-19 is much higher than the positive reference, while the least active 1167.12-14 is much worse than the positive reference, which further illustrates the importance of modification for siRNA activity. Next, we conducted a liver homogenate stability test on the sequences with good activity to evaluate the stability of the sequence in vivo.
[0242] Table 10: Results of liver homogenate stability experiments with different modified siRNAs
[0243] siRNA Residual ratio of antisense strand at 72h (%) 1167.3-5 70.74 1167.3-16 58.98 1167.16-5 79.27 1167.16-16 68.00 1167.17-17 90.89 1167.17-19 91.16
[0244] As can be seen from Table 10, the stability of the sequences in liver homogenate varies with the modification. The most active 1167.17-19 is also more stable in liver homogenate than other modified 1167 sequences.
[0245] Table 11: Experimental results of 0.1 nM modified siRNA delivered by liposomes in primary hepatocytes of humanized AGT mice
[0246]
[0247] Table 12: Results of liver homogenate stability experiments with different modified siRNAs
[0248] siRNA Residual ratio of antisense strand at 72h (%) 1167.17-19 81.96 1167.22-19 86.08 1167.23-19 68.25 1167.24-19 59.74
[0249] From Tables 11 and 12, we found that different endings have a great influence on the activity and stability of the 1167 sequence. When 1167 ends with mGmG, both the activity and stability are much higher than those of mCmC, dTdT or mAmA.
[0250] Table 13: Experimental results of 0.3 nM modified siRNA delivered by L96 in AGT / PCSK9 dual humanized mouse primary hepatocytes
[0251]
[0252] As can be seen from Table 13, the activity of 1167.25-19 modified with VPU-S is comparable to that of 1167.17-19 modified with VPU.
[0253] We further optimized the two sequences 1165 and 1161 with good activity and high safety, and tested the changes in in vitro activity when different modifications and bases were changed.
[0254] Table 14: Experimental results of 0.3 nM modified siRNA duplex delivered by L96 in primary hepatocytes of AGT / PCSK9 dual humanized mice
[0255]
[0256]
[0257] The preferred sequences 1161 and 1165 were further optimized by changing the bases and modifications. It was found that the VPU-S modification had a great influence on the activity of the two sequences. Among them, for sequence 1161, 1161.4-13, 1161.5-14, and 1161.7-15, the three modifications had the best activity. For sequence 1165, 1165.8-17, 1165.5-14, and 1165.5-16, the three modifications had good activity. And the activity of these preferred sequences was much higher than the positive reference 1000PM.
[0258] Table 15: Experimental results of different concentrations of modified siRNA delivered by SL01 in primary hepatocytes of AAV8-AGT / ANGPTL3 mice
[0259]
[0260] For the preferred sequences 1161.7-15, 1161.7-17, 1165.5-14, 1165.5-16, 1167.25-19, 1167.27-21, the in vitro activity of the siRNA duplex delivered by SL01 was evaluated at 1 nM and 0.1 nM concentrations. As shown in Table 15, at 1 nM and 0.1 nM, the activity of the preferred sequences was higher than that of the Alnylam positive reference, and the best activity was 1167.25-19, 1165.5-14 and 1165.5-16.
[0261] Next, we evaluated several preferred sequences in vivo.
[0262] Table 16: Experimental results of hAGT protein expression level after AGT-targeted siRNA was delivered into AAV8-hAGT mice via L96 at a dose of 1 mg / kg
[0263]
[0264] As can be seen from Table 16, the in vivo activity of 1167.25-19, 1167.27-21, and 1165.5-16 is much better than the positive reference, especially in terms of long-term effectiveness. On day 74, the inhibition rate of AGT expression by the positive reference 1000PM was only 20%, while the inhibition rate of AGT expression by the preferred sequences 1167.25-19, 1167.27-21, and 1165.5-16 was still about 50%. We next tested the in vivo activity of the preferred sequences delivered by SL01.
[0265] Table 17: Experimental results of hAGT protein expression level after hAGT targeting siRNA was delivered into AAV8-hAGT / hPCSK9 mice via SL01 at a dose of 1 mg / kg
[0266]
[0267]
[0268] The two sequences with the best activity were further verified in vivo. The positive reference was delivered by L96, and 1167.25-19 and 1165.5-16 were delivered by SL01. It can be seen that the activity of the two preferred sequences is much better than that of the positive reference.
[0269] Example 6 Synthesis of siRNA targeting PCSK9
[0270] The synthesis method is as in Example 1. The duplex 11000PM is the drug inclisiran that has been approved for marketing, with patent number CN108220295B, and is used as a positive comparison sequence.
[0271] Table 18: Sense and antisense strand sequences of unmodified siRNA targeting PCSK9
[0272]
[0273]
[0274]
[0275]
[0276] Next, we modified the siRNA to improve its stability in vivo and in vitro, enhance its activity against the target, and reduce its activity against non-targets. Unless otherwise stated, L96 delivery was used for in vivo and in vitro screening of single-target sequences to more realistically reflect the effect of liver-targeted siRNA. The 3' end of the sense strand of siRNA was connected to L96.
[0277] Table 19: Modified siRNA sequences targeting PCSK9
[0278]
[0279]
[0280]
[0281]
[0282]
[0283]
[0284]
[0285] Example 7 Experimental results of in vitro activity and stability of siRNA targeting PCSK9
[0286] Humanized PCSK9 mice were purchased from Shanghai Model Organisms Science Co., Ltd., and the primary hepatocyte extraction experimental method and cell target gene qPCR detection method were referred to Example 2.
[0287] Primers for detecting PCSK9 are as follows:
[0288] Forward primer: ACGTGGCTGGCATTGCA (SEQ ID NO: 708)
[0289] Reverse primer: AAGTGGATCAGTCTCTGCCTCAA (SEQ ID NO: 709)
[0290] Probe: CATGATGCTGTCTGCCGAGCCG (SEQ ID NO: 710) (reporter gene 5'NED, quencher group 3'BHQ1)
[0291] Table 20: Experimental results of liposome transfection of modified siRNA at different concentrations in Hep3B cells
[0292]
[0293]
[0294] NA means not detected
[0295] Table 21: Experimental results of different concentrations of modified siRNA in humanized PCSK9 mouse primary hepatocytes delivered by liposome transfection or L96
[0296]
[0297] Table 22: Experimental results of 10 nM modified siRNA delivered by L96 in humanized PCSK9 mouse primary hepatocytes
[0298]
[0299]
[0300] The in vitro activity data of Hep3B and humanized PCSK9 mouse liver primary cells showed that the activities of multiple sequences including 11002.1-1, 11040.1-1 and 11042.1-1 were better than the positive reference. Next, we tested the activity of these sequences in humanized PCSK9 mice.
[0301] Example 8 Evaluation of the effect of a single subcutaneous injection of 1 mg / kg siRNA on PCSK9 protein expression in humanized PCSK9 mice
[0302] Experimental methods:
[0303] 1. Experimental grouping and drug administration
[0304] Before the experiment, the mice were blooded from the submandibular vein to obtain whole blood. The blood samples were allowed to stand at room temperature for 30 minutes, centrifuged at 1000×g for 10 minutes, and the supernatant serum was taken and stored in a -80 degree refrigerator. The serum samples were diluted 1000 times, and the expression of PCSK9 in mouse serum was detected by Human PCSK9 ELISA Kit (proteintech, Cat No: KE00278). Based on the PCSK9 expression level, the mice were evenly divided into groups, with 4 mice in each group. siRNA was dissolved in physiological saline and the concentration was adjusted to 0.1 mg / ml. The mice were subcutaneously injected with siRNA solution at a dose of 1 mg / kg.
[0305] 2.ELISA test
[0306] After siRNA injection, a small amount of blood was collected from the submandibular vein at regular intervals, left to stand at room temperature for 30 minutes, centrifuged at 1000×g for 10 minutes, and the supernatant serum was collected. After diluting 1000 times, the PCSK9 expression level was detected by ELISA.
[0307] The experimental results are shown in Table 23.
[0308] Table 23: Experimental results of PCSK9 targeted siRNA inhibiting PCSK9 protein expression level in humanized PCSK9 mice at a dose of 1 mg / kg
[0309]
[0310] The data showed that the inhibition rate of serum PCSK9 protein reached its maximum on the 30th day after administration, and then rebounded. On the 40th day, the PCSK9 protein in the positive reference group remained at about 89.7%, and the inhibition rate was about 10.3%. The inhibition rates of the remaining experimental groups were higher than the positive reference, especially 11040.1-6 and 11042.1-15, the inhibition rates were all greater than 50%, and the inhibition rate of 11002.1-8 was also 46.8%. On the 55th day, the inhibition rate of the 11042.1-15 group was still 50%. The activity of 11040.1-6 was higher than that of 11040.1-8, indicating that even with the same sequence, different modifications have different activities in the body.
[0311] Example 9 Safety test of siRNA targeting PCSK9
[0312] The siRNA safety test method is shown in Example 4, and the experimental results are shown in Table 24.
[0313] Table 24: Safety test results of siRNA targeting PCSK9
[0314] siRNA ALT(U / L) AST(U / L) Normal saline 47 154 11002.7-14 47 172 11040.3-10 39 85 11042.1-15 526 320
[0315] Note: Data for 11042.1-15 are for testing 10 days after the second injection.
[0316] From Table 24, we can see that 11002.7-14 and 11040.3-10 are very safe in mice, while 11042.1-15 has a great impact on liver function in mice.
[0317] Effects of different modifications and base changes on sequence activity and stability in Examples 1011002 and 11040
[0318] Table 25: Experimental results of 1 nM modified siRNA delivered by L96 in primary hepatocytes of humanized PCSK9 mice
[0319]
[0320] It can be concluded from Table 25 that for the same sequence, different positive chain modifications have a great influence on the activity. The modification activity of 11040.1-23 is the best.
[0321] Table 26: Experimental results of 3nM modified siRNA delivery via L96 in humanized PCSK9 mouse primary hepatocytes
[0322]
[0323] It can be concluded from Table 26 that the activity changes are different when the bases and modifications are changed in different sequences.
[0324] Table 27: Metabolic stability data of different modified siRNA in liver homogenate
[0325] siRNA Residual ratio of antisense strand at 72h (%) 11000PM 68.26 11002.1-1 73.45 11002.3-10 70.31 11002.5-14 63.18 11002.7-14 86.41 11040.1-1 107.97 11040.3-10 48.69 11040.5-10 24.93 11040.7-18 25.32
[0326] It can be concluded from Table 27 that different sequence modifications and base changes have different effects on stability. Among them, 11002.7-14 and 11040.1-1 are very stable in liver homogenate, while the stability of 11002.5-14 and 11040.5-10 is significantly reduced.
[0327] Table 28: Experimental results of different concentrations of modified siRNA delivered by L96 or liposome transfection in humanized PCSK9 mouse primary hepatocytes
[0328]
[0329] Table 29: Experimental results of different concentrations of modified siRNA delivered by L96 or liposome transfection in humanized PCSK9 mouse primary hepatocytes
[0330]
[0331] Table 30: Experimental results of 0.3 nM modified siRNA delivered by liposomes in primary hepatocytes of AVV8-hPCSK9 mice
[0332]
[0333] Table 31: Experimental results of 0.1 nM modified siRNA transfection in primary hepatocytes of AVV8-hPCSK9 mice by liposome transfection
[0334]
[0335] Table 32: Experimental results of different concentrations of modified siRNA delivered by L96 in primary hepatocytes of AVV8-hPCSK9 mice
[0336]
[0337]
[0338] The experimental data in Tables 28-32 show that we optimized the 11002 and 11040 sequences from multiple aspects such as the sense strand and the antisense strand. The results show that the activities of the preferred sequences 11002.17-21, 11002.10-23 and 11040.10-23 are better than the positive reference 11000PM. Next, we verified the activity of the preferred sequences in vivo.
[0339] Table 33: Experimental results of PCSK9 targeted siRNA inhibiting PCSK9 protein expression level in humanized PCSK9 mice at a dose of 1 mg / kg
[0340]
[0341] It can be concluded from Table 33 that the in vivo activities of 11002.17-21 and 11040.10-23 are much better than the positive reference 1000PM.
[0342] Example 11 Synthesis of siRNA targeting ANGPTL3
[0343] The specific synthesis method is shown in Example 1.
[0344] Table 34: Sense and antisense sequences of unmodified siRNA targeting ANGPTL3
[0345]
[0346]
[0347]
[0348]
[0349]
[0350]
[0351]
[0352] Next, we modified the siRNA to improve its stability in vivo and in vitro, enhance its activity against the target, and reduce its activity against non-targets. Unless otherwise stated, L96 delivery was used for in vivo and in vitro screening of single-target sequences to more realistically reflect the effect of liver-targeted siRNA. The 3' end of the sense strand of siRNA was connected to L96.
[0353] 7000PM (AD-1331212) is the optimal sequence in US11613751B2. ARO-ANG3 is the optimal sequence in US10995335B2 and is used as a positive comparison sequence. The sequence information is shown in Table 34. To examine the sequence activity, the same GalNAc was used for delivery.
[0354] Table 35: Modified siRNA sequences targeting ANGPTL3
[0355]
[0356]
[0357]
[0358]
[0359]
[0360]
[0361]
[0362]
[0363]
[0364]
[0365]
[0366]
[0367]
[0368] Example 12 In vitro activity evaluation of siRNA targeting ANGPTL3
[0369] The method for evaluating the in vitro activity of Hep3B cells is referred to Example 2. When primary hepatocytes are used for in vitro activity evaluation, the method for obtaining transgenic mice stably expressing hANGPTL3 and extracting primary hepatocytes is referred to Example 2.
[0370] The primers for detecting ANGPTL3 are as follows:
[0371] Forward primer: ACATGTGGCTGAGATTGCTGG (SEQ ID NO: 711)
[0372] Reverse primer: CCTTTGCTCTGTGATTCCATGTAG (SEQ ID NO: 712)
[0373] Probe: CCTCCCAGAGCACACAGACCTGATGTTT (SEQ ID NO: 713) (reporter gene 5'NED, quencher group 3'MGB)
[0374] Table 36: Experimental results of different concentrations of modified siRNA in Hep3B and humanized ANGPTL3 mouse primary hepatocytes by liposome transfection or L96 delivery
[0375]
[0376]
[0377] NA means not detected
[0378] The activity of the modified siRNA was evaluated in Hep3B cells and humanized ANGPTL3 mouse primary hepatocytes by liposome transfection and free uptake, respectively. From the data in the table, it can be seen that the activity of many sequences is better than the positive reference. Next, we will evaluate their in vivo activity. The results are shown in Table 37 below.
[0379] Example 13 Evaluation of the Effect of In Vitro Preferred Sequences on hANGPTL3 Expression in the Liver in AAV8-hANGPTL3 Mice The effect of in vitro preferred sequences on hANGPTL3 expression in the liver was evaluated in mice expressing hANGPTL3.
[0380] Experimental methods:
[0381] 1. Adenoviral integration of hANGPTL3
[0382] Pass 1-10x10 11 The recombinant AAV8 virus particles were titered and purified and then infected into mice to obtain transgenic mice stably expressing hANGPTL3.
[0383] 2. Drug administration
[0384] 14 days after the mice were injected with the virus, the mice were divided into groups, with 4 mice in each group. siRNA was dissolved in physiological saline and injected subcutaneously at a dose of 1 mg / kg or 3 mg / kg.
[0385] 3. Liver sampling and testing
[0386] The liver was harvested at different time points after siRNA injection, and RNA in the liver tissue was extracted by TRI REAGENT (MRC, Catalog No.: TR118), and the extracted RNA was reverse transcribed into cDNA using PrimeScript RT regent Kit (Takara, Catalog No.: RR047A). The prepared QPCR system was added to a 96-well PCR plate, sealed with a plate sealer, and QPCR was performed on the StepOnePlus real-time PCR system (appliedbiosystems) to detect the expression of hANGPTL3.
[0387] Table 37: Experimental results of ANGPTL3 targeted siRNA inhibiting hANGPTL3 gene expression level in the liver of AAV8-hANGPTL3 mice at a dose of 1 mg / kg
[0388]
[0389]
[0390] NA means not detected
[0391] siRNAs with better in vitro activity were screened for in vivo activity at a dose of 1 mg / kg. The experimental results are shown in Table 37. 7061.1-11 had the best activity, which was much better than the positive reference ARO-ANG3.
[0392] Table 38: Experimental results of 0.3 nM modified siRNA delivery via L96 in AAV8-hAGT / hANGPTL3 mouse primary hepatocytes
[0393]
[0394] From Table 38, it can be concluded that the activities of 7061.9-13 and 7061.1-11 are much higher than the positive reference ARO-ANG3
[0395] Table 39: Experimental results of 0.3 nM modified siRNA transfection in Hep3B cells by liposome
[0396]
[0397] From Table 39, it can be concluded that the in vitro activities of many sequences are better than or equivalent to the positive reference. Among them, the 7061.9-13 sequence has the best activity. We selected the sequences with better activity in the table and evaluated their activity in AAV8-hANGPTL3 mice.
[0398] Table 40: AAV8-hANGPTL3 mouse in vivo experimental data
[0399]
[0400]
[0401] In vivo activity screening was performed at a dose of 1 mg / kg, and the experimental results are shown in Table 40. On day 28, the activity of sequences 7061.9-13 and 7083.1-1 was better than the positive reference ARO-ANG3. Sequence 7061 was further optimized, and the activity of the adjacent sequences of 7061 was tested at the same time.
[0402] Table 41: Experimental results of 1 nM modified siRNA delivery via L96 in humanized ANGPTL3 mouse primary hepatocytes
[0403]
[0404] Sequence 7061 was further optimized based on its modified siRNA 7061.9-13, and the in vitro activity was evaluated in humanized ANGPTL3 mouse primary hepatocytes. As can be seen from Table 41, the activity of 7061 varies greatly with different modifications. Among them, 7061.4-16 has the highest activity. We also compared the activities of sequences 7094.1-1, 7095.1-1, and 7096.1-1 adjacent to sequence 7061. It can be seen that under the same modification, the activity of 7061 is significantly better than that of its adjacent sequences.
[0405] We further evaluated the activity of 7061.18-14 and 7061.4-16 in primary hepatocytes from humanized ANGPTL3 mice. The results are shown in Table 42.
[0406] Table 42: Experimental results of 1 nM modified siRNA delivery via L96 in humanized ANGPTL3 mouse primary hepatocytes
[0407]
[0408] From Table 42, it can be concluded that the activities of 7061.18-14 and 7061.4-16 are much higher than the positive reference ARO-ANG3.
[0409] Next, we tested the safety of sequences 7061 and 7083. The experimental results are shown in Table 43
[0410] Table 43: Safety test results of siRNA targeting ANGPTL3
[0411] siRNA ALT(U / L) AST(U / L) Normal saline 31 121 7061.1-11 38 133 7083.9-2 484 639
[0412] From Table 43 we can see that 7061.1-11 is very safe in mice, while 7083.9-2 has a great impact on the liver function of mice.
[0413] Next, we will conduct further activity evaluation in vivo.
[0414] Example 14 Activity evaluation of optimized siRNA of sequence 7061 in AAV8-hANGPTL3 mice
[0415] Table 44: Results of in vivo activity evaluation of preferred sequences
[0416]
[0417]
[0418] The activity of sequence 7061.4-16 was evaluated in vivo in AAV8-hANGPTL3 mice at a dose of 1 mg / kg by SL01 delivery. As can be seen from Table 44, the activity of 7061.4-16 is better than the positive reference.
[0419] Through the above single-target screening, we have found sequences with better activity for each target. Next, we use the following structure to connect the single-target sequences with better activity into a whole, so that it can inhibit the expression of two genes at the same time.
[0420] Example 15 Preparation of SL01-CPG
[0421]
[0422]
[0423] Preparation of compound 1a-1: (3R, 5S)-5-(bis(4-methoxyphenyl)(phenyl)methoxy)methyl)pyrrolidin-3-ol (10 g, 23.84 mmol, 1.0 eq), 12-methoxy-12-oxodecanoic acid (5.8 g, 23.84 mmol, 1.0 eq), N,N-diisopropylethylamine (12.3 g, 95.36 mmol, 4.0 eq) in dichloromethane
[0424] The mixture was stirred at room temperature for 2.0 hours (100 ml). The mixture was washed with sodium carbonate solution, and the aqueous phase was extracted with dichloromethane (50 ml x 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 100 / 1 to 20 / 1) to obtain a yellow oil product 1a-1 (16.7 g, yield: 79.3%).
[0425] Preparation of compound 1a-2: Add lithium hydroxide monohydrate (3.1 g, 64.73 mmol, 2.5 eq.) to a mixture of tetrahydrofuran / methanol / water (80 ml / 16 ml / 16 ml) of compound 1a-1 (16.7 g, 25.89 mmol, 1.0 eq.). The mixture is reacted at 40°C for 4 hours. The reaction solution is decompressed to remove the solvent. The residual aqueous solution is freeze-dried. The residue is dissolved in dichloromethane and filtered. The filtrate is concentrated under reduced pressure to obtain a white solid product 1a-2 (14.3 g, yield: 85.3%). LCMS (ESI): m / z=630[M-1] - .
[0426] Preparation of compound 1a-3: Benzyl chloroformate (2.03 g, 11.88 mmol, 1.2 eq.) was added to a mixture of tetrahydrofuran (20 ml) and water (10 ml) of compound (azadiylbis(ethane-2,1-diyl))carbamic acid tert-butyl ester (3.0 g, 9.9 mmol, 1.0 eq.) and sodium carbonate (1.57 g, 14.85 mmol, 1.5 eq.). The mixture was stirred at room temperature overnight. The mixture was diluted with water (50 ml) and then extracted with ethyl acetate (20 ml x 3). The combined organic layer was washed with saturated brine (20 ml x 1), dried over anhydrous sodium sulfate and concentrated. The residue was subjected to column chromatography on silica gel (petroleum ether: ethyl acetate = 3: 1) to obtain a white solid product 1a-3 (3.80 g, yield: 88%). LCMS (ESI): m / z = 438 [M+1] +.
[0427] Preparation of compound 1a-4: To a mixture of compound 1a-3 (3.74 g, 8.55 mmol, 1.0 eq.) in methanol (10 ml) was added a solution of hydrogen chloride-dioxane (4 mol / L, 15 ml). The mixture was stirred at room temperature for 1.5 hours. The solvent was removed under reduced pressure. The residue was dried under vacuum to give a white solid product 1a-4 (2.92 g, crude). LCMS (ESI): m / z=238[M+1] + .
[0428] Preparation of compound 1a-5: To a mixture of compound (S)-4-(tert-butoxy)-3-((tert-butoxycarbonyl)amino)-4-oxobutanoic acid (45 g, 155.54 mmol, 1.0 eq.) and N-methylmorpholine (15.7 g, 155.54 mmol, 1.0 eq.) in tetrahydrofuran (220 ml) was added dropwise isobutyl chloroformate (20.17 ml, 155.54 mmol, 1.0 eq.) at -20°C. After the mixture was stirred for 10 minutes, the mixture was filtered. To the filtrate was slowly added a solution of sodium borohydride (11.8 g, 311.08 mmol, 2.0 eq.) in water (70 ml) at -30°C. The mixture was warmed to 0°C and stirred for 0.5 hours. The mixture was diluted with water (200 ml) and then extracted with ethyl acetate (100 ml×3). The combined organic layers were washed with saturated brine (100 mL x 1), dried over anhydrous sodium sulfate and concentrated to obtain a colorless oil 1a-5 (43.67 g, crude product). LCMS (ESI): m / z = 276 [M+1] + .
[0429] Preparation of compound 1a-6: At 0°C, Dess-Martin reagent (79.2 g, 186.65 mmol, 1.2 eq.) was added to a mixture of compound 1a-5 (42.8 g, 155.54 mmol, 1.0 eq.) and sodium bicarbonate (39.2 g, 466.62 mmol, 3.0 eq.) in dichloromethane (300 ml). The mixture was warmed to room temperature and stirred for 2 hours. The mixture was filtered. The filtrate was concentrated under reduced pressure. The residue was diluted with ethyl acetate (200 ml), washed with saturated sodium thiosulfate solution (100 ml × 1), saturated sodium bicarbonate solution (100 ml × 1) and saturated brine (100 ml × 1), dried over anhydrous sodium sulfate and concentrated to give a light yellow oil 1a-6 (40 g, crude product). LCMS (ES I): m / z = 274 [M+1] + .
[0430] Preparation of compound 1a-7: A mixture of benzylamine (6.1 g, 57.01 mmol, 1.0 eq), compound 1a-6 (38 g, 139.2 mmol, 2.44 eq) and acetic acid (3.26 ml, 57.01 mmol, 1.0 eq) in methanol (200 ml) was stirred at room temperature for 10 minutes. The mixture was cooled to 0°C, and then sodium cyanoborohydride (12.53 g, 199.54 mmol, 3.5 eq) was slowly added. The mixture was warmed to room temperature and stirred overnight. The solvent was removed under reduced pressure, and the residue was diluted with water (150 ml). Solid sodium bicarbonate was added to adjust pH = 9, and the aqueous layer was extracted with ethyl acetate (60 ml × 3). The combined organic layers were washed with saturated brine (50 ml × 1), dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography on silica gel (petroleum ether: ethyl acetate = 50: 1 to 5: 1) to obtain a colorless oil 1a-7 (24.1 g, yield: 68%). LCMS (ESI): m / z 622 [M+1] + .
[0431] Preparation of compound 1a-8: To a mixture of compound 1a-7 (27.5 g, 44.23 mmol, 1.0 eq.) and N,N-diisopropylethylamine (1.54 ml, 8.85 mmol, 0.2 eq.) in acetonitrile (125 ml) was added dropwise 1-chloroethyl chloroformate (7.16 ml, 66.34 mmol, 1. eq.) at 0°C. The mixture was warmed to room temperature and stirred for 2 hours. The solvent was removed under reduced pressure. The residue was diluted with methanol (20 ml). The mixture was heated to 63°C and stirred for 1.5 hours. The solvent was removed under reduced pressure, and the residue was diluted with dichloromethane (150 ml). The organic layer was washed with saturated sodium bicarbonate solution (30 ml x 1) and saturated brine (50 ml x 1), dried over anhydrous sodium sulfate and concentrated. The residue was subjected to column chromatography on silica gel (dichloromethane: methanol = 200: 1 to 20: 1) to obtain a light yellow oil 1a-8 (11.5 g, yield: 49%). LCMS (ESI): m / z = 532 [M+1] + .
[0432] Preparation of compound 1a-9: 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (9.84 g, 23.78 mmol, 1.1 eq.) was added to a mixture of compound 1a-8 (4.3 g, 22.7 mmol, 1.05 eq.) and 3-(tert-butyloxycarbonyl)amino)propionic acid (4.3 g, 22.7 mmol, 1.05 eq.) and N,N-diisopropylethylamine (5.58 g, 43.24 mmol, 2.0 eq.) in dichloromethane (70 ml). The mixture was stirred at room temperature for 2.5 hours. The solvent was removed under reduced pressure. The residue was subjected to column chromatography on silica gel (petroleum ether: ethyl acetate = 4: 1 to 2: 1) to obtain a light yellow solid product 1a-9 (14.98 g, yield: 99%). LCMS (ESI): m / z = 703 [M+1] + .
[0433] Preparation of compound 1a-10: A mixture of hydrogen chloride-dioxane (4 mol / L, 90 ml) of compound 1a-9 (14.9 g, 21.19 mmol, 1.0 eq) was stirred overnight at room temperature. The solvent was removed under reduced pressure. The residue was dissolved in tetrahydrofuran (100 ml) and water (100 ml). Sodium carbonate (13.48 g, 127.14 mmol, 6.0 eq) and di-tert-butyl carbonate (24.36 ml, 105.95 mmol, 5.0 eq) were added. The mixture was stirred at room temperature for 48 hours. Tetrahydrofuran was removed under reduced pressure. The residue was diluted with water (200 ml) and then washed with dichloromethane (60 ml × 4). A 2 mol / L dilute hydrochloric acid solution was added to the aqueous layer to adjust the pH to 3, and then extracted with ethyl acetate (60 ml × 4). The combined organic layer was washed with saturated brine (50 mL x 1), dried over anhydrous sodium sulfate and concentrated to obtain a light yellow solid product 1a-10 (10.5 g, yield: 84%). LCMS (ESI): m / z = 592 [M+1] + .
[0434] Preparation of compound 1a-11: Compound 1a-10 (3.76 g, 6.36 mmol, 1.0 eq.), compound 1a-4 (1.97 g, 6.36 mmol, 1.0 eq.) and N,N-diisopropylethylamine (4.92 g, 38.16 mmol, 6.0 eq.) in dichloromethane (60 ml) were added dropwise to a mixture of 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (6.58 g, 15.9 mmol, 2.5 eq.) at 0°C over 30 minutes. The mixture was warmed to room temperature and stirred for 20 minutes. The solvent was removed under reduced pressure. The residue was diluted with saturated sodium bicarbonate solution (50 ml) and then extracted with ethyl acetate (30 ml x 3). The combined organic layer was washed with saturated brine (50 ml x 1), dried over anhydrous sodium sulfate and concentrated. The residue was subjected to column chromatography on silica gel (ethyl acetate: methanol = 50: 1 to 30: 1) to obtain a white solid product 1a-11 (1.97 g, yield: 39%). LCMS (ESI): m / z = 792 [M+1] + .
[0435] Preparation of compound 1a-13: A mixture of 1a-11 (1.97 g, 2.49 mmol, 1.0 eq) in hydrogen chloride-dioxane (4 mol / L, 13 ml) was stirred at room temperature for 1.5 hours. The solvent was removed under reduced pressure. The residue was diluted with dichloromethane (60 ml). Compound 1a-12 (3.34 g, 7.47 mmol, 3.0 eq), N, N-diisopropylethylamine (2.57 g, 19.92 mmol, 8.0 eq) and 2-(7-azabenzotriazole)-N, N, N', N'-tetramethyluronium hexafluorophosphate (3.03 g, 7.97 mmol, 3.2 eq) were added. The mixture was stirred at room temperature for 1.5 hours. The mixture was washed with saturated sodium bicarbonate solution (30 ml × 2) and saturated brine (30 ml × 1), dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography on silica gel (dichloromethane: methanol = 30: 1, plus 1% triethylamine) to obtain a light yellow solid product 1a-13 (3.43 g, yield: 77%). LCMS (ESI): m / z = 1780 [M+1] + .
[0436] Preparation of compound 1a-14: Palladium hydroxide / carbon (10%, 0.69 g) was added to a mixture of compound 1a-13 (3.47 g, 1.95 mmol, 1.0 eq.) and trifluoroacetic acid (0.15 ml, 1.95 mmol, 1.0 eq.) in isopropanol (50 ml) and ethanol (25 ml). The mixture was stirred at room temperature for 20 hours under hydrogen balloon pressure. The mixture was filtered. The filtrate was concentrated under reduced pressure to give a white solid product 1a-14 (3.45 g, crude product). LCMS (ESI): m / z=1646[M+1] + .
[0437] Preparation of compound 1a-15 (Compound 31): 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.26 g, 0.68 mmol, 1.2 eq.) was added to a mixture of compound 1a-14 (1.0 g, 0.57 mmol, 1.0 eq.), compound 1a-2 (0.396 g, 0.63 mmol, 1.1 eq.) and N,N-diisopropylethylamine (0.441 g, 3.42 mmol, 6.0 eq.) in dichloromethane (15 ml). The mixture was stirred at room temperature for 2.5 hours. The solvent was removed under reduced pressure. The residue was purified by preparative HPLC (A: pH = 7 phosphate buffer, B: acetonitrile, acetonitrile concentration 50%-70% within 30 minutes) to obtain a white solid product 1a-15 (Compound 31) (0.45 g, yield: 35%). LCMS (ESI): m / z = 980 [(M-302+2) / 2] + .
[0438] Preparation of compound 1a-16: Succinic anhydride (34.5 mg, 0.348 mmol, 6.0 eq.) was added to a mixture of compound 1a-15 (130 mg, 0.058 mmol, 1.0 eq.), triethylamine (70 mg, 0.696 mmol, 12.0 eq.) and 4-dimethylaminopyridine (3.5 mg, 0.029 mmol, 0.5 eq.) in dichloromethane (1 ml). The mixture was stirred at room temperature for 2 days. The mixture was diluted with dichloromethane (10 ml), then washed with saturated sodium bicarbonate solution (5 ml × 2) and saturated brine (5 ml × 1), dried over anhydrous sodium sulfate and concentrated to give a white solid product 1a-16 (111 mg, yield: 81%). LCMS (ESI): m / z = 1030.5 [(M-302) / 2+H] + .1H NMR(500MHz,DMSO)δ8.42–8.25(m,2H),8.06(t,J=25.8Hz,2H),7.89–7.70(m ,4H),7.30(dd,J=14.4,6.9Hz,4H),7.20(dd,J=10.1,6.9Hz,5H),6.93–6.84 (m,4H),6.58(d,J=5.9Hz,1H),5.76(s,1H),5.21(s,3H),4.97(d,J=13.1Hz, 3H),4.50(d,J=8.2Hz,3H),4.20(s,3H),4.02(s,9H),3.87(dd,J=18.8,9.5H z,3H),3.80–3.63(m,11H),3.41(d,J=8.7Hz,10H),3.24(s,2H),3.20–3.12( m,3H),3.03(dd,J=26.7,13.8Hz,3H),2.47(d,J=9.6Hz,3H),2.44–2.36(m,4 H),2.31–2.18(m,5H),2.11(d,J=10.6Hz,13H),2.07(s,2H),2.03(d,J=7.3H z,3H),1.99(s,9H),1.89(s,9H),1.77(s,12H),1.47(s,16H),1.25(s,11H).
[0439] Preparation of compound SL01-CPG: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (21 mg, 0.056 mmol, 1.2 eq.) and 1-hydroxybenzotriazole (9 mg, 0.066 mmol, 1.4 eq.) were added to a mixture of compound 1a-16 (111 mg, 0.047 mmol, 1.0 eq.) and N,N-diisopropylethylamine (36 mg, 0.282 mmol, 6.0 eq.) in N,N-dimethylformamide (5.5 ml). The mixture was shaken at room temperature for 5 minutes. CPG-NH2 (0.167 mmol / g, 550 mg, 0.092 mmol, 1.95 eq.) was added and the mixture was shaken at room temperature for 22 hours. The mixture was filtered, and the filter cake was washed with dichloromethane, acetonitrile, and dichloromethane and dried under vacuum for 1 hour. The residue was added with pyridine / acetic anhydride (3 ml / 1 ml) and shaken at room temperature for 3 hours. The mixture was filtered, and the filter cake was washed with dichloromethane, acetonitrile, and dichloromethane, and dried under vacuum for 1 hour to obtain a white solid product SL01-CPG (578 mg, loading: 35 μmol / g).
[0440] Example 16 Preparation of Intermediate M
[0441]
[0442] To a mixture of 11-aminoundecanoic acid (5 g, 24.8 mmol, 1.0 eq.) and triethylamine (2.5 g, 24.8 mmol, 1.0 eq.) in methanol (50 ml) was added ethyl 2,2,2-trifluoroacetate (4.4 g, 31.0 mmol, 1.25 eq.). The mixture was stirred at room temperature overnight. The methanol was removed under vacuum, the residue was dissolved in water, and the pH was adjusted to 1 to 2 with 1 mol hydrochloric acid solution. The mixture was extracted with ethyl acetate, the organic phase was washed with saturated brine, and concentrated under vacuum to give a yellow oily product 11-(2,2,2-trifluoroacetamide)undecanoic acid (Intermediate M-1, 6.16 g, yield: 83.4%). LCMS (ESI): m / z=298 [M+H] + .
[0443] To a mixture of 11-(2,2,2-trifluoroacetamide)undecanoic acid (6.06 g, 20.4 mmol, 1.0 eq), (3R,5S)-5-(bis(4-methoxyphenyl)(phenyl)methoxy)methyl)pyrrolidin-3-ol (8.55 g, 20.4 mmol, 1.0 eq) and N,N-diisopropylethylamine (7.8 g, 61.2 mmol, 3.0 eq) in N,N-dimethylformamide (60 ml) was added 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (8.1 g, 21.4 mmol, 1.05 eq). The mixture was stirred at room temperature for 1 hour. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated brine and concentrated under vacuum. The residue was purified by silica gel column (eluent: petroleum ether / ethyl acetate = 2 / 1 to 3 / 1, plus 0.5% triethylamine) to give the product N-(11-((2S, 4R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxypyrrolidin-1-yl)-11-oxoundecyl)-2,2,2-trifluoroacetamide (intermediate M-2, 11.6 g, yield: 80.7%) as a white solid. LCMS (ESI): m / z = 699 [M+H] + .
[0444] A mixture of N-(11-((2S, 4R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxypyrrolidin-1-yl)-11oxonadecanyl)-2,2,2-trifluoroacetamide (11.6 g, 16.5 mmol, 1.0 eq.) and potassium hydroxide (9.3 g, 165 mmol, 10.0 eq.) in methanol (110 ml) was stirred at room temperature overnight. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated brine and concentrated under vacuum. The residue was purified by silica gel column (eluent: dichloromethane / methanol=50 / 1, plus 0.5% triethylamine) to give yellow oily product intermediate M (9.24 g, yield: 92.4%). LCMS (ESI): m / z=603[M+H] + .
[0445] Example 17 Preparation of DL07-CPG
[0446]
[0447]
[0448] Preparation of compound 2b-2: A mixture of compound 2b-1 (22.02 g, 50.00 mmol, 1.0 eq), (2-aminoethyl) benzyl carbamate (9.71 g, 50.00 mmol, 1.0 eq), N, N-diisopropylethylamine (12.90 g, 10.00 mmol, 2.0 eq) and 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (21.72 g, 52.50 mmol, 1.05 eq) in N, N-dimethylformamide (250 ml) was stirred at room temperature for 30 minutes. The mixture was diluted with water and then filtered. The filter cake was washed with water. The filter cake was dried to give a white solid product 2b-2 (crude product). LCMS (ESI): m / z=617 [M+H] + . 1 HNMR (500MHz, DMSO) δ7.87(t,J=8.1Hz,3H),7.67(d,J=6.9Hz,2H),7.42(d,J=7.4Hz,2H),7.37–7.26(m,7H),7.19(d,J=4.7Hz,2H),6.84(d,J=7.2H z,1H),5.00(s,2H),4.34–4.15(m,3H),3.90(d,J=5.0Hz,1H),3.19–2.94 (m,6H),1.78(d,J=6.6Hz,1H),1.62(dd,J=13.1,6.6Hz,1H),1.37(s,9H).
[0449] Preparation of compound 2b-3: A mixture of compound 2b-2 (crude product) in piperidine / acetonitrile (50 ml / 200 ml) was stirred at room temperature for 1 hour. The mixture was filtered, the filtrate was concentrated, and the residue was purified by silica gel column chromatography (eluent: dichloromethane to dichloromethane / methanol = 20 / 1) to give a yellow solid product 2b-3 (15.0 g, yield: 76.14%).
[0450] LCMS (ESI): m / z=395 [M+H] + .
[0451] Preparation of compound 2b-4: A mixture of compound 2b-3 (7.80 g, 19.80 mmol, 1.5 eq.), (2-bromoethyl) tert-butyl carbamate (2.96 g, 13.20 mmol, 1.0 eq.) and potassium carbonate (3.64 g, 26.40 mmol, 2.0 eq.) in N,N-dimethylformamide (80 ml) was stirred at room temperature overnight. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 100 / 1 to 50 / 1) to give a colorless oily product 2b-4 (4.0 g, yield: 56.43%). LCMS (ESI): m / z = 538 [M+H] + . 1 H NMR (500MHz, DMSO) δ7.92(s,1H),7.42–7.28(m,5H),7.19(s,1H),6.93(d,J=7.3Hz,1H),6.75(s,1H),5.01(s,2H),3.95(d,J=5.4Hz ,1H),3.14(ddd,J=18.3,12.5,6.1Hz,2H),3.05(d,J=5.5Hz,4H),2.68–2.56(m,4H),1.79(s,1H),1.72–1.60(m,1H),1.37(s,18H).
[0452] Preparation of compound 2b-6: A mixture of compound 2b-4 (4.0 g, 7.45 mmol, 1.0 eq), compound 2b-5 (2.39 g, 7.08 mmol, 0.95 eq), N, N-diisopropylethylamine (1.92 g, 14.90 mmol, 2.0 eq) and 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (3.08 g, 7.45 mmol, 1.0 eq) in N, N-dimethylformamide (50 ml) was stirred at room temperature for 1 hour. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 60 / 1) to give a white solid product 2b-6 (4.4 g, yield: 72.52%). LCMS (ESI): m / z=858 [M+H] + . 1H NMR(500MHz,DMSO)δ7.88(d,J=12.6Hz,1H),7.32(d,J=22.7Hz,10H),7.26– 7.13(m,2H),7.01–6.65(m,2H),5.25–5.03(m,2H),5.00(s,2H),4.10–3.96( m,1H),3.82(s,1H),3.17(d,J=43.7Hz,6H),3.03(d,J=22.8Hz,4H),2.43–2. 21(m,2H),2.03–1.86(m,1H),1.79(s,2H),1.63(s,1H),1.44–1.29(m,27H).
[0453] Preparation of compound 2b-7: A solution of compound 2b-6 (4.4 g, 5.13 mmol, 1.0 eq.) in hydrogen chloride-dioxane (40 ml) was stirred at room temperature for 1 hour. The solvent was removed under vacuum. The residue was used directly in the next step without purification (crude product). LCMS (ESI): m / z=557 [M+H] + .
[0454] Preparation of compound 2b-8: A mixture of 2b-7 (crude), N, N-diisopropylethylamine (6.60 g, 51.16 mmol, 10.0 eq.), compound 1a-12 (7.10 g, 15.87 mmol, 3.1 eq.) and 2-(7-azabenzotriazole)-N, N, N', N'-tetramethyluronium hexafluorophosphate (6.20 g, 16.31 mmol, 3.2 eq.) in acetonitrile (70 ml) was stirred at room temperature for 1 hour. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 50 / 1 to 25 / 1) to give a yellow solid product 2b-8 (6.0 g, yield: 63.39%). LCMS (ESI): m / z = 923 [M / 2+H] + .
[0455] Preparation of compound 2b-9: Under a hydrogen atmosphere, a mixture of compound 2b-8 (6.0 g, 3.25 mmol, 1.0 eq), palladium hydroxide / carbon (1.5 g, 25% mass fraction) and trifluoroacetic acid (371 mg, 3.25 mmol, 1.0 eq) in ethanol (100 ml) was stirred at room temperature overnight. The mixture was filtered through diatomaceous earth. The filter cake was washed with ethanol and the filtrate was concentrated. The residue was used directly in the next step without purification (5.0 g, yield: 94.93%). LCMS (ESI): m / z=811[M / 2+H] + .
[0456] Preparation of compound 2b-10: Under nitrogen protection, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (40.2 g, 210 mmol, 1.1 eq) was added to a mixture of 6-azidohexanoic acid (30 g, 190.8 mmol, 1.0 eq) and 1-hydroxypyrrolidine-2,5-dione (24 g, 210 mmol, 1.1 eq) in dichloromethane / N,N-dimethylformamide (270 / 30 ml). The mixture was stirred overnight at room temperature. Dichloromethane was removed under vacuum, 1 mol per liter hydrochloric acid solution and methyl tert-butyl ether were added, the liquids were separated, and the organic layer was washed with sodium bicarbonate solution and saturated brine. The organic phase was dried and concentrated under vacuum to obtain a yellow oily product 2b-10 (46.8 g, yield: 96.8%). LCMS (ESI): m / z=255[M+1] + .
[0457] Preparation of compound 2b-11: A mixture of compound 2b-9 (5.0 g, 3.09 mmol, 1.0 eq), compound 2b-10 (824 mg, 3.24 mmol, 1.05 eq) and N,N-diisopropylethylamine (1.19 g, 9.22 mmol, 3.0 eq) in acetonitrile (60 ml) was stirred at room temperature for 1 hour. The reaction was directly carried out to the next step without post-treatment. LCMS (ESI): m / z=881 [M / 2+H] + .
[0458] Preparation of compound 2b-12 (compound 54): A mixture of compound 2b-11 (crude), intermediate M (2.04 g, 3.39 mmol, 1.1 eq), N,N-diisopropylethylamine (796 mg, 6.17 mmol, 2.0 eq) and 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (1.4 g, 3.39 mmol, 1.1 eq) in acetonitrile (60 ml) was stirred for 1 hour. The mixture was directly purified by high performance liquid chromatography (chromatographic column: UniSil 10-120C18, 30×250 mm) to obtain a white solid product 2b-12 (compound 54) (3.1 g, yield: 42.79%). LCMS (ESI): m / z=1022[(M-302) / 2+H] +.1H NMR (500MHz, DMSO) δ8.04–7.72(m,9H),7.30(dd,J=17.9,8.1Hz,4H),7.23–7.10(m,5H),6.93–6.81(m,4H),5.76(s,1H),5.21(d,J=2.3Hz,3H) ,5.02–4.83(m,4H),4.49(d,J=8.2Hz,3H),4.15(s,3H),4.02(s,9H),3. 87(q,J=9.5Hz,3H),3.72(d,J=12.9Hz,9H),3.41(s,3H),3.29(d,J=6.8 Hz,2H),3.07(ddd,J=23.5,22.3,17.2Hz,14H),2.22(dd,J=22.2,15.1Hz,4H),2.11(d,J=13.0Hz,13H),2.04(dd,J=14.3,6.9Hz,5H),1.99(s,1 0H),1.89(s,9H),1.84(d,J=13.3Hz,3H),1.77(s,9H),1.68(d,J=35.4H z,2H),1.50(dd,J=14.8,7.4Hz,19H),1.35(s,3H),1.30–1.18(m,13H).
[0459] Preparation of compound 2b-13: A mixture of compound 2b-12 (3.1 g, 1.32 mmol, 1.0 eq), succinic anhydride (793 mg, 7.93 mmol, 6.0 eq), triethylamine (1.60 g, 15.84 mmol, 12.0 eq) and 4-dimethylaminopyridine (16 mg, 0.13 mmol, 0.1 eq) in dichloromethane (25 ml) was stirred at room temperature for 6 hours. The mixture was washed with 10% sodium bicarbonate solution and acetonitrile. The organic phase was concentrated to give a light purple solid product 2b-13 (3.4 g, crude product). LCMS (ESI): m / z=1072[(M-302) / 2+H] + .
[0460] Preparation of compound DL07-CPG: To a solution of compound 2b-13 (300 mg, 0.12 mmol, 1.0 eq.) in N,N-dimethylformamide was added 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate
[0461] (56 mg, 0.15 mmol, 1.2 eq), 1-hydroxybenzotriazole (23 mg, 0.17 mmol, 1.4 eq) and N,N-diisopropylethylamine (63 mg, 0.49 mmol, 4.0 eq), the mixture was shaken at room temperature for 5 minutes. 1.5 g of CPG-NH2 was added to the mixture and shaken overnight at room temperature. The mixture was filtered, the filter cake was washed with dichloromethane, acetonitrile, and dichloromethane and dried under vacuum for 1 hour. Pyridine / acetic anhydride (12 ml / 4 ml) was added to the residue and shaken at room temperature for 3 hours. The mixture was filtered, the filter cake was washed with dichloromethane, acetonitrile, and dichloromethane, and dried under vacuum for 1 hour to obtain a light yellow solid product DL07-CPG (1.61 g, loading: 41.1 μmol / g).
[0462] Example 18 Preparation of DL09-CPG
[0463]
[0464] Preparation of compound 4a-2: Under nitrogen protection, a mixture of compound 4a-1 (10 g, 62 mmol, 1.0 eq.), compound 2b-10 (17 g, 68 mmol, 1.1 eq.) and N,N-diisopropylethylamine (18 g, 136 mmol, 2.2 eq.) in acetonitrile (100 ml) was stirred at room temperature overnight. Acetonitrile was removed under vacuum, 1 mol hydrochloric acid solution and methyl tert-butyl ether were added, the liquids were separated, and the organic layer was washed with water and saturated brine. The organic phase was dried and concentrated under vacuum to give a yellow oily product 4a-2 (18.5 g, yield: 99.4%). LCMS (ESI): m / z=301[M+1] + .
[0465] Preparation of compound 4a-3: 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (28 g, 67.6 mmol, 1.1 eq) was added to a mixture of compound 4a-2 (18.5 g, 61.5 mmol, 1.0 eq), tert-butyl 3-(2-aminoethoxy) propionate (11.6 g, 61.5 mmol, 1.0 eq) and N,N-diisopropylethylamine (17.4 g, 135.2 mmol, 2.0 eq) in N,N-dimethylformamide (180 ml). The mixture was stirred at room temperature for 1 hour. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated brine and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1 to dichloromethane / methanol = 20 / 1) to obtain the product 4a-3 (14.8 g, yield: 51.4%) as a white solid. LCMS (ESI): m / z = 472 [M+1] + .
[0466] Preparation of compound 4a-4: A mixture of compound 4a-3 (8.86 g, 20.7 mmol, 1.0 eq.) in trifluoroacetic acid / dichloromethane (10 / 50 ml) was stirred at room temperature for 5.0 hours. The mixture was concentrated under vacuum to give a yellow oily product 4a-4 (8 g, crude product). LCMS (ESI): m / z=416 [M+1] + .
[0467] Preparation of compound 4a-5: 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (8.1 g, 19.7 mmol, 1.1 eq) was added to a mixture of compound 4a-4 (8.86 g, 18.7 mmol, 1.0 eq), (3R, 5S)-5-(bis(4-methoxyphenyl)(phenyl)methoxy)methyl)pyrrolidin-3-ol (7.8 g, 18.7 mmol, 1.0 eq) and N,N-diisopropylethylamine (9.6 g, 75 mmol, 4.0 eq) in N,N-dimethylformamide (90 ml). The mixture was stirred at room temperature for 1 hour. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated brine and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluent: petroleum ether / dichloromethane / methanol = 50 / 50 / 1 to 30 / 30 / 1) to give the product 4a-5 (7.5 g, yield: 49%) as a white solid. LCMS (ESI): m / z = 817 [M+1] + .
[0468] Preparation of compound 4a-6: A mixture of compound 4a-5 (7.5 g, 9.19 mmol, 1.0 eq) and lithium hydroxide monohydrate (1.1 g, 27.5 mmol, 3.0 eq) in tetrahydrofuran / methanol / water (60 / 30 / 30 ml) was stirred at room temperature overnight. The mixture was diluted with water and washed with methyl tert-butyl ether. The aqueous phase was extracted with dichloromethane. The organic phase was concentrated under vacuum to give a pale white solid product 4a-6 (4.68 g, yield: 63.4%) LCMS (ESI): m / z=801[M-1] - .
[0469] Preparation of compound 4a-7 (compound 53): 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (148 mg, 0.39 mmol, 1.2 eq.) was added to a mixture of compound 1a-14 (570 mg, 0.32 mmol, 1.0 eq.), compound 4a-6 (260 mg, 0.32 mmol, 1.0 eq.) and N,N-diisopropylethylamine (146 mg, 1.13 mmol, 3.5 eq.) in N,N-dimethylformamide (2.5 ml). The mixture was stirred at room temperature overnight. The mixture was purified by preparative high performance liquid chromatography (A: pH = 7 phosphate buffer, B: acetonitrile, acetonitrile concentration 30%-90% within 30 minutes) to obtain a white solid product 4a-7 (compound 53) (245 mg, yield: 31%). LCMS(ESI): m / z=1065[(M-302+2) / 2] + .
[0470] Preparation of compound 4a-8: Succinic anhydride (60.5 mg, 0.60 mmol, 6.0 eq.) was added to a mixture of compound 4a-7 (245 mg, 0.10 mmol, 1.0 eq.), triethylamine (121 mg, 1.2 mmol, 12.0 eq.) and 4-dimethylaminopyridine (12 mg, 0.10 mmol, 1.0 eq.) in dichloromethane (2 ml). The mixture was stirred at room temperature for 20 hours. The mixture was diluted with dichloromethane (10 ml), then washed with saturated sodium bicarbonate solution (10 ml × 2) and saturated brine (10 ml × 1), dried over anhydrous sodium sulfate and concentrated to give a white solid product 4a-8 (275 mg, crude product). LCMS (ESI): m / z = 1115 [(M-302+2) / 2] + .
[0471] Preparation of compound DL09-CPG: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (57 mg, 0.15 mmol, 1.5 eq.) and 1-hydroxybenzotriazole (20 mg, 0.15 mmol, 1.5 eq.) were added to a mixture of compound 4a-8 (253 mg, 0.10 mmol, 1.0 eq.) and N,N-diisopropylethylamine (77 mg, 0.60 mmol, 6.0 eq.) in N,N-dimethylformamide (10 ml). The mixture was shaken at room temperature for 5 minutes. CPG-NH2 (0.167 mmol / g, 1.27 g, 0.21 mmol, 2.1 eq.) was added and the mixture was shaken at room temperature for 22 hours. The mixture was filtered, and the filter cake was washed with dichloromethane, acetonitrile, and dichloromethane and dried under vacuum for 1 hour. The residue was added with pyridine / acetic anhydride (12 ml / 4 ml) and shaken at room temperature for 3 hours. The mixture was filtered, the filter cake was washed with dichloromethane, acetonitrile, dichloromethane, and dried under vacuum for 1 hour to obtain a white solid DL09-CPG (1.36 g, loading: 30 μmol / g).
[0472] Example 19 Preparation of DL15-CPG
[0473]
[0474] Preparation of compound 15a-1: To a mixture of compound 10a-5 (6.0 g, 14.7 mol, 1.5 eq.) and (2-bromoethyl)carbamic acid tert-butyl ester (2.2 g, 9.8 mmol, 1.0 eq.) in 30 ml of dimethylformamide, potassium carbonate (5.07 g, 36.75 mmol, 2.5 eq.) was added at room temperature and stirred overnight. The mixture was diluted with ethyl acetate and washed with water and saturated brine. The organic phase was concentrated to dryness under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 30 / 1 to 10 / 1, with ammonia water) to give a white solid compound 15a-1 (3.29 g, yield: 60.8%). LCMS (ESI): m / z = 552 (M+H) + .
[0475] Preparation of compound 15a-2: Compound 15a-1 (1.7 g, 3.08 mmol, 1.0 eq), compound 10a-2 (3.2 g, 9.97 mmol, 3.2 eq), acetic acid (185 mg, 3.08 mmol, 1.0 eq) and sodium cyanoborohydride (626 mg, 9.97 mmol, 3.2 eq) were added to 24 ml of methanol. The mixture was stirred at room temperature for 96 hours, concentrated under reduced pressure, sodium carbonate solution was added, and extracted with ethyl acetate. The organic phase was washed with water and saturated brine and concentrated to dryness under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol=40 / 1 to 10 / 1, ammonia water was added) to obtain white solid compound 15a-2 (1.72 g, yield: 54.0%). LCMS (ESI): m / z=857.5 (M+H) + .
[0476] Preparation of compound 15a-3: Compound 15a-2 (1.72 g, 2.01 mmol, 1.0 eq.) was added to 20 ml of 4M hydrogen chloride-dioxane solution. The mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to obtain compound 15a-3 (1.57 g, crude product). LCMS (ESI): m / z=557 (M+H) + .
[0477] Preparation of compound 15a-4: Crude compound 15a-3 (1.57 g, 2.01 mmol, 1.0 eq), compound 1a-12 (2.87 g, 6.41 mol, 3.2 eq), diisopropylethylamine (2.58 g, 20.1 mmol, 10.0 eq) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2.87 g, 6.41 mmol, 3.2 eq) were added to 35 ml of acetonitrile, and the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added. The organic phase was washed with water and saturated brine and concentrated to dryness under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 40 / 1 to 15 / 1, triethylamine was added) to obtain white solid compound 15a-4 (2.01 g, yield: 54.1%). LCMS (ESI): m / z=1845 (M+H) + .
[0478] Preparation of compound 15a-5: Compound 15a-4 (2.0 g, 1.08 mmol, 1.0 eq) was dissolved in 45 ml of ethanol, and trifluoroacetic acid (160 mg, 1.41 mmol, 1.3 eq) and 300 mg of 10% palladium hydroxide / carbon were added. The mixture was stirred at room temperature overnight under a hydrogen atmosphere. The mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain a white solid compound 15a-5 (2.0 g, crude product). LCMS (ESI): m / z=1621 (M+H) + .
[0479] Preparation of compound 15a-6: Compound 15a-5 (2.0 g, 1.08 mmol, 1.0 eq), diisopropylethylamine (418 mg, 3.24 mmol, 3.0 eq) and compound 2b-10 (307 mg, 1.21 mmol, 1.12 eq) were added to 15 ml of acetonitrile, and the mixture was stirred at room temperature for 1.5 hours. Diisopropylethylamine (209 mg, 1.62 mmol, 1.5 eq), 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (538 mg, 1.30 mmol, 1.2 eq) and intermediate M (783 mg, 1.30 mmol, 1.2 eq) were added, and the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added. The organic phase was washed with water and saturated brine and concentrated to dryness under reduced pressure. The residue was purified by preparative liquid chromatography (eluent: pH 7.0 potassium dihydrogen phosphate-potassium hydroxide buffer solution / acetonitrile) to give white solid compound 15a-6 (1.81 g, yield: 37.1%). LCMS (ESI): m / z=1022 ((M-302) / 2+H) + .
[0480] Preparation of compound 15a-7: Under nitrogen protection, compound 15a-6 (300 mg, 0.128 mmol, 1.0 eq), triethylamine (155 mg, 1.54 mmol, 12.0 eq), succinic anhydride (77 mg, 0.768 mmol, 6.0 eq) and p-dimethylaminopyridine (1.6 mg, 0.013 mmol, 0.1 eq) were added to 1.5 ml of dichloromethane, and the mixture was stirred at room temperature overnight. The mixture was diluted with dichloromethane / acetonitrile, washed with 10% sodium bicarbonate solution and saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give compound 15a-7 (375 mg, crude) as a white solid. LCMS (ESI): m / z=1072 ((M-302) / 2+H) + .
[0481] Preparation of compound DL15-CPG: Compound 15a-7 (375 mg, 0.128 mmol, 1.0 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (68 mg, 0.179 mmol, 1.4 eq), 1-hydroxybenzotriazole (28 mg, 0.205 mmol, 1.6 eq) and diisopropylethylamine (76 mg, 0.59 mmol, 4.6 eq) were added to 13 ml of dimethylformamide, and the mixture was stirred at room temperature for 5 minutes. 1.735 g of CPG-NH2 was added, and the mixture was shaken at room temperature overnight. The mixture was filtered, the solid phase was washed with dichloromethane and acetonitrile, and the solid phase was dried under reduced pressure. 10 ml of pyridine and 3.4 ml of acetic anhydride were added, and the mixture was shaken for 3 hours. The solid phase was filtered, washed with dichloromethane and acetonitrile, and dried under reduced pressure to obtain a yellow solid compound DL15-CPG (1.39 g, 37.5 μmol / g).
[0482] Example 20 Preparation of DL16-CPG
[0483]
[0484] Preparation of compound 16a-1: Under nitrogen protection, a solution of 2,4-dinitrobenzenesulfonyl chloride (2.6 g, 9.7 mmol, 1.2 eq) in tetrahydrofuran (10 ml) was added dropwise to a mixture of compound 2b-3 (3.2 g, 8.1 mmol, 1.0 eq) and N,N-diisopropylethylamine (2.0 g, 16.2 mmol, 2.0 eq) in tetrahydrofuran (40 ml) under ice bath conditions. The mixture was stirred for 1 hour under ice bath. Ethyl acetate was added to the mixture, washed with water, diluted hydrochloric acid, sodium bicarbonate aqueous solution, brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a brown solid 16a-1 (6.0 g, crude product). LCMS (ESI): m / z=582[M+H] + .
[0485] Preparation of compound 16a-2: Compound 16a-1 (1 g, 1.6 mmol, 1.0 eq), (tert-butyloxycarbonyl)-L-homoserine benzyl ester (1.24 g, 4.0 mmol, 2.5 eq) and triphenylphosphine (1.26 g, 4.8 mmol, 3.0 eq) were added to 30 ml of toluene and stirred at room temperature for 5 minutes. Diethyl azodicarboxylate (0.835 g, 4.8 mmol, 3.0 eq) was added dropwise under an ice bath, and the mixture was stirred at room temperature for 2 hours. The mixture was filtered. The residue was dissolved in 30 ml of dichloromethane and 30 ml of petroleum ether was added. The mixture was stirred at room temperature for 1 hour. The mixture was filtered. The residue was washed with dichloromethane / petroleum ether (1 / 1). Drying gave yellow solid compound 16a-2 (1.42 g, yield: 96.59%). LCMS (ESI): m / z = 916 (M+H)+ .
[0486] Preparation of compound 16a-3: Compound 16a-2 (1.6 g, 1.75 mmol, 1.0 eq) and triethylamine (530 mg, 5.25 mmol, 3.0 eq) were added to 10 ml of dichloromethane. 2-Mercaptoacetic acid (322 mg, 3.5 mmol, 2.0 eq) was added and the mixture was stirred at room temperature for 10 minutes. Ethyl acetate was added for extraction. The organic phase was washed with aqueous sodium carbonate solution and saturated brine. There was evidence of concentrating under reduced pressure to obtain compound 16a-3 (1.2 g, crude) as a yellow oil. LCMS (ESI): m / z=686 (M+H) + .
[0487] Preparation of compound 16a-4: Compound 16a-3 (1.2 g, 1.75 mmol, 1.0 eq), 3-(tert-butyloxycarbonyl)amino)propionic acid (331 mg, 1.75 mmol, 1.0 eq), diisopropylethylamine (451 mg, 3.5 mmol, 2.0 eq) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (798 mg, 2.1 mmol, 1.2 eq) were added to 30 ml of dichloromethane, and the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added for extraction. The organic phase was washed with water and saturated brine and concentrated to dryness under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 25 / 1 to 10 / 1, triethylamine was added) to give white solid compound 16a-4 (740 mg, yield: 49.33%). LCMS (ESI): m / z=858 (M+H) + .
[0488] Preparation of compound 16a-5: Compound 16a-4 (740 mg, 0.86 mmol, 1.0 eq.) was added to 5 ml of 4M hydrogen chloride-dioxane solution. The mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to obtain yellow solid compound 16a-5 (482 mg, crude product). LCMS (ESI): m / z=557 (M+H) + .
[0489] Preparation of compound 16a-6: Compound 16a-5 (482 mg, 0.86 mmol, 1.0 eq), compound 1a-12 (1.2 g, 2.68 mmol, 3.1 eq), diisopropylethylamine (1.12 g, 8.64 mmol, 10.0 eq) and 2-(7-azobenzotriazole)-N, N, N', N'-tetramethyluronium hexafluorophosphate (1.05 g, 2.76 mmol, 3.2 eq) were added to 10 ml of acetonitrile, and the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added for extraction. The organic phase was washed with water and saturated brine and concentrated to dryness under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 25 / 1 to 10 / 1, triethylamine was added) to give white solid compound 16a-6 (879 mg, yield: 55.28%). LCMS (ESI): m / z=1844 (M+H) + .
[0490] Preparation of compound 16a-7: Compound 16a-6 (879 mg, 0.476 mmol, 1.0 eq) was dissolved in 5 ml of ethanol, and trifluoroacetic acid (54 mg, 0.476 mmol, 1.0 eq) and 88 mg of 10% palladium hydroxide / carbon were added. The mixture was stirred at room temperature overnight under a hydrogen atmosphere. The mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain a white solid compound 16a-7 (800 mg, crude product). LCMS (ESI): m / z=1621 (M+H) + .
[0491] Preparation of compound 16a-8 (compound 65): Compound 16a-7 (800 mg, 0.476 mmol, 1.0 eq), diisopropylethylamine (184 mg, 1.428 mmol, 3 eq) and compound 2b-10 (133 mg, 0.523 mmol, 1.1 eq) were added to 10 ml of acetonitrile, and the mixture was stirred at room temperature for 1.5 hours. Diisopropylethylamine (184 mg, 1.428 mmol, 3 eq), 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (236 mg, 0.57 mmol, 1.2 eq) and intermediate M (343 mg, 0.57 mmol, 1.2 eq) were added, and the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added for extraction. The organic phase was washed with water and saturated brine and concentrated to dryness under reduced pressure. The residue was purified by preparative liquid chromatography (eluent: pH 7.0 potassium dihydrogen phosphate-potassium hydroxide buffer solution / acetonitrile) to obtain yellow solid compound 16a-8 (343 mg, yield: 30.90%). LCMS (ESI): m / z=1022 ((M-302) / 2+H) + .
[0492] Preparation of compound 16a-9: Compound 16a-8 (343 mg, 0.146 mmol, 1.0 eq), triethylamine (177 mg, 1.752 mmol, 12.0 eq), succinic anhydride (88 mg, 0.878 mmol, 6.0 eq) and p-dimethylaminopyridine (2 mg, 0.014 mmol, 0.1 eq) were added to 5 ml of dichloromethane, and the mixture was stirred at room temperature overnight. The mixture was diluted with dichloromethane, washed with 10% sodium bicarbonate solution and saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give yellow solid compound 16a-9 (396 mg, crude product). LCMS (ESI): m / z=1072 ((M-302) / 2+H) + .
[0493] Preparation of compound DL16-CPG: Compound 16a-9 (396 mg, 0.162 mmol, 1.0 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (74 mg, 0.194 mmol, 1.2 eq), 1-hydroxybenzotriazole (30 mg, 0.226 mmol, 1.4 eq) and diisopropylethylamine (84 mg, 0.648 mmol, 4.0 eq) were added to 10 ml of dimethylformamide, and the mixture was stirred at room temperature for 5 minutes. 1.58 g of CPG-NH2 was added, and the mixture was shaken at room temperature overnight. The mixture was filtered, the solid phase was washed with dichloromethane and acetonitrile, and the solid phase was dried under reduced pressure. 9 ml of pyridine and 3 ml of acetic anhydride were added, and the mixture was shaken for 3 hours. The solid phase was filtered, washed with dichloromethane and acetonitrile, and dried under reduced pressure to obtain a yellow solid compound DL16-CPG (1.68 g, loading: 45.7 μmol / g).
[0494] Example 21 Preparation of DL18-CPG
[0495]
[0496]
[0497] Preparation of compound 18a-2: Benzyl bromide (13.1 ml, 109.89 mmol, 2.5 eq.) was added to a mixture of compound 18a-1 (4.0 g, 43.96 mmol, 1.0 eq.) and potassium carbonate (18.2 g, 131.88 mmol, 3.0 eq.) in ethanol (40 ml). The mixture was heated to reflux for 3 hours. The solvent was removed under reduced pressure. The residue was diluted with water (60 ml) and then extracted with dichloromethane (50 ml x 2). The combined organic layer was washed with saturated brine (50 ml x 1), dried over anhydrous sodium sulfate and concentrated. The residue was subjected to column chromatography on silica gel (dichloromethane: methanol 80: 1) to obtain white solid compound 18a-2 (9.89 g, yield: 83%). LCMS (ES I): m / z 272 [M+1] + ; TLC: Rf 0.5 (dichloromethane:methanol ester=50:1).
[0498] Preparation of compound 18a-3: Sodium hydroxide (15 g, 375 mmol, 15 eq.) was added to a mixture of compound 18a-2 (6.7 g, 24.72 mmol, 1.0 eq.), tert-butyl bromoacetate (28.78 g, 147.55 mmol, 6.0 eq.) and tetrabutylamine hydrogensulfate (1.26 g, 3.71 mmol, 0.15 eq.) in water (50 ml) and toluene (65 ml). The mixture was heated to 50°C and reacted for 40 hours. The mixture was diluted with water (50 ml) and then extracted with dichloromethane (50 ml x 2). The combined organic layer was washed with saturated brine (50 ml x 1), dried over anhydrous sodium sulfate and concentrated. The residue was subjected to column chromatography on silica gel (petroleum ether: ethyl acetate 50: 1) to obtain a colorless oily compound 18a-3 (3.61 g, yield: 29%). LCMS (ESI): m / z 500 [M+1] + ; TLC: Rf 0.5 (petroleum ether:ethyl acetate=30:1).
[0499] Preparation of compound 18a-4: A mixture of compound 18a-3 (3.73 g, 7.46 mmol, 1.0 eq) in hydrogen chloride-dioxane (4M, 20 ml,) was stirred at room temperature overnight. The solvent was removed under reduced pressure. The residue was diluted with dichloromethane (40 ml). Ammonium chloride (2.39 g, 44.76 mmol, 6.0 eq), N, N-diisopropylethylamine (7.7 g, 59.68 mmol, 8.0 eq) and 2-(7-azabenzotriazole)-N, N, N', N'-tetramethyluronium hexafluorophosphate (8.51 g, 22.38 mmol, 3.0 eq) were added. The mixture was stirred at room temperature for 7 hours. The solvent was removed under reduced pressure. The residue was diluted with a saturated sodium carbonate solution (50 ml) and then extracted with ethyl acetate (20 ml x 3). The combined organic layer was washed with saturated brine (30 mL x 1), dried over anhydrous sodium sulfate and concentrated to give a pale yellow oily compound 18a-4 (3.5 g, crude product). LCMS (ESI): m / z 386 [M+1] + ; TLC: Rf 0.5 (dichloromethane:methanol=20:1).
[0500] Preparation of compound 18a-5: Borane dimethyl sulfide complex (10M, 5.97 ml, 59.7 mmol, 8.0 equiv) was added to a mixture of compound 18a-4 (2.87 g, 7.46 mmol, 1.0 equiv) in tetrahydrofuran (40 ml,). The mixture was heated to 65°C for 5 hours. The mixture was quenched with water (25 ml). Sodium carbonate (2.37 g, 22.38 mmol, 3.0 equiv) and di-tert-butyl dicarbonate (4.88 g, 22.38 mmol, 3.0 equiv) were added. The mixture was stirred at room temperature for 3 hours. The mixture was diluted with water (50 ml) and then extracted with ethyl acetate (30 ml, ×2). The combined organic layer was washed with saturated brine (30 ml ×1), dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography on silica gel (petroleum ether: ethyl acetate 8: 1 to 3: 1) to obtain compound 18a-5 (741 mg, yield: 18%) as a pale yellow oil. LCMS (ESI): m / z 558 [M+1] + ; TLC: Rf 0.5 (petroleum ether:ethyl acetate=5:1).
[0501] Preparation of compound 18a-6: To a mixture of compound 18a-5 (741 mg, 1.33 mmol, 1.0 eq.) in methanol (2 ml) was added a solution of hydrogen chloride-dioxane (4 M, 5 ml). The mixture was stirred at room temperature for 1 hour. The solvent was removed under reduced pressure. The residue was dried under vacuum to obtain a crude white solid compound 18a-6. LCMS (ESI): m / z 358 [M+1] +; TLC: Rf 0.2 (dichloromethane:methanol=10:1).
[0502] Preparation of compound 18a-7: Compound 1a-10 (786 mg, 1.33 mmol, 1.0 eq.), compound 18a-6 (616 mg, 1.33 mmol, 1.0 eq.) and N,N-diisopropylethylamine (1.03 g, 7.98 mmol, 6.0 eq.) in dichloromethane (15 ml) were added dropwise to a mixture of 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (1.38 g, 3.33 mmol, 2.5 eq.) at 0°C over 30 minutes. The mixture was warmed to room temperature and stirred for 20 minutes. The solvent was removed under reduced pressure. The residue was diluted with saturated sodium carbonate solution (30 ml) and then extracted with ethyl acetate (20 ml x 3). The combined organic layer was washed with saturated brine (20 ml x 1), dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography on silica gel (ethyl acetate: methanol 50: 1 to 30: 1) to give white solid compound 18a-7 (0.42 g, yield: 35%). LCMS (ESI): m / z 911 [M+1] + ; TLC: Rf 0.3 (ethyl acetate:dichloromethane=1:1).
[0503] Preparation of compound 18a-8: A mixture of compound 18a-7 (0.42 g, 0.46 mmol, 1.0 eq.) in hydrogen chloride-dioxane (4M, 4 ml,) was stirred at room temperature for 1 hour. The solvent was removed under reduced pressure. The residue was diluted with dichloromethane (10 ml). Compound 1a-12 (618 mg, 1.38 mmol, 3.0 eq.), N,N-diisopropylethylamine (475 mg, 3.68 mmol, 8.0 eq.) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (525 mg, 1.38 mmol, 3.0 eq.) were added. The mixture was stirred at room temperature for 1 hour. The mixture was diluted with dichloromethane (20 ml), washed with saturated sodium bicarbonate solution (20 ml x 2) and saturated brine (20 ml x 1), dried over anhydrous sodium sulfate and concentrated. The residue was separated by column chromatography on silica gel (dichloromethane: methanol: triethylamine 30: 1: 0.3) to give white solid compound 18a-8 (778 mg, yield: 89%). LCMS (ESI): m / z 1900 [M+1] + ; TLC: Rf 0.5 (dichloromethane:methanol=10:1).
[0504] Preparation of compound 18a-9: Palladium hydroxide / carbon (10%, 0.5 g) was added to a mixture of compound 18a-8 (778 mg, 0.409 mmol, 1.0 eq.) and trifluoroacetic acid (47 mg, 0.409 mmol, 1.0 eq.) in methanol (10 ml) and ethanol (5 ml). The mixture was stirred at room temperature overnight under hydrogen balloon pressure. The mixture was filtered. The filtrate was concentrated under reduced pressure to give a light yellow solid compound 18a-9 (600 mg, crude product). LCMS (ESI): m / z 1720 [M+1] + ; TLC: Rf 0.3 (dichloromethane:methanol=10:1).
[0505] Preparation of compound 18a-10: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (188 mg, 0.495 mmol, 1.5 eq.) was added to a mixture of compound 18a-9 (600 mg, 0.33 mmol, 1.0 eq.), compound 4a-6 (265 mg, 0.33 mmol, 1.0 eq.) and N,N-diisopropylethylamine (255 mg, 1.98 mmol, 6.0 eq.) in N,N-dimethylformamide (2 ml). The mixture was stirred at room temperature for 0.5 hours. The mixture was purified by preparative liquid chromatography (A: pH = 7 phosphate buffer, B: acetonitrile, acetonitrile concentration 30%-90% within 30 minutes) to obtain white solid compound 18a-10 (180 mg, yield: 22%). LCMS(ESI): m / z1102[(M-302+2) / 2] + ; TLC: Rf 0.5 (dichloromethane:methanol=10:1).
[0506] Preparation of compound 18a-11: To a mixture of compound 18a-10 (180 mg, 0.072 mmol, 1.0 eq), triethylamine (87 mg, 0.862 mmol, 12.0 eq) and 4-dimethylaminopyridine (4.4 mg, 0.036 mmol, 0.5 eq) in dichloromethane (2 ml), succinic anhydride (43 mg, 0.43 mmol, 6.0 eq) was added. The mixture was stirred at room temperature for 20 hours. The mixture was diluted with dichloromethane (10 ml), then washed with saturated sodium bicarbonate solution (10 ml × 2) and saturated brine (10 ml × 1), dried over anhydrous sodium sulfate and concentrated to give white solid compound 18a-11 (155 mg, yield: 83%). LCMS (ESI): m / z 1152 [(M-302+2) / 2] + ; TLC: Rf 0.3 (dichloromethane:methanol=10:1).
[0507] Preparation of compound DL18-CPG: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (34 mg, 0.09 mmol, 1.5 eq.) and 1-hydroxybenzotriazole (12 mg, 0.09 mmol, 1.5 eq.) were added to a mixture of compound 18a-11 (155 mg, 0.06 mmol, 1.0 eq.) and N,N-diisopropylethylamine (46 mg, 0.36 mmol, 6.0 eq.) in N,N-dimethylformamide (8 ml). The mixture was stirred at room temperature for 5 minutes. CPG-NH2 (0.167 mmol / g, 775 mg, 0.13 mmol, 2.2 eq.) was added. The mixture was stirred at room temperature overnight. The mixture was filtered. The solid was washed with dichloromethane (8 ml x 5). Pyridine (6 ml) and acetic anhydride (2 ml) were added. The mixture was stirred at room temperature for 3 hours. The mixture was filtered. The solid was washed with dichloromethane (8 mL x 5) and dried under vacuum to obtain a white solid compound DL18-CPG (785 mg, 21.5 μmol / g, yield: 29%).
[0508] Example 22 Preparation of DL20-CPG
[0509]
[0510] Preparation of compound 20a-1: Compound di-tert-butyl dicarbamate (5.0 g, 16.48 mmol, 1.00 eq.), ethyl 2-bromoacetate (3.1 g, 18.13 mmol, 1.1 eq.), potassium carbonate (4.5 g, 32.96 mmol, 2.0 eq.) were reacted in N,N-dimethylformamide (40 ml) at room temperature overnight. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated to give a yellow oily product 20a-1 (6.4 g, crude product). LCMS (ESI): m / z=390 [M+H] + .
[0511] Preparation of compound 20a-2: Compound 20a-1 (6.2 g, 15.94 mmol, 1.0 eq.), lithium hydroxide monohydrate (1.6 g, 39.85 mmol, 2.5 eq.) in tetrahydrofuran + methanol + aqueous solution (40 ml + 10 ml + 10 ml) were stirred at 40°C for 2.5 hours. Water was added to the mixture, 2 molar dilute hydrochloric acid was added to adjust the pH to 5, and the aqueous phase was extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated to give compound 20a-2 (5.1 g, crude product). LCMS (ESI): m / z=362[M+H] + .
[0512] Preparation of compound 20a-3: Compound 2b-2 (13.6 g, 22.05 mmol, 1.00 eq) was reacted in trifluoroacetic acid / dichloromethane solution (50 ml / 100 ml) at room temperature for 1 hour. The mixture was spin-dried. The residue was adjusted to pH 8 by adding water. The organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated to give a white solid product 20a-3 (6.1 g, yield: 53.6%). LCMS (ESI): m / z=517 [M+H] + .
[0513] Preparation of compound 20a-4: Compound 20a-2 (4.3 g, 11.82 mmol, 1.0 eq), compound 20a-3 (6.1 g, 11.82 mmol, 1.0 eq), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (5.4 g, 14.18 mmol, 1.2 eq), diisopropylethylamine (3.1 g, 23.04 mmol, 2.0 eq) were stirred in N,N-dimethylformamide (50 ml) at room temperature for 1 hour. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue was stirred with dichloromethane / petroleum ether = 1:1. The mixture was filtered to give yellow solid compound 20a-4 (10 g, crude). LCMS (ESI): m / z = 861 [M+H] + .
[0514] Preparation of compound 20a-5: A solution of compound 20a-4 (9.5 g, 11.05 mmol, 1.0 eq.) in diethylamine / acetonitrile (20 / 80 ml) was stirred at room temperature for 1 hour. The mixture was purified by silica gel column chromatography (eluent: dichloromethane to dichloromethane / methanol = 10 / 1) to give a yellow solid product 20a-5 (5.1 g, yield: 72.5%). LCMS (ESI): m / z = 638 [M+H] + .
[0515] Preparation of compound 20a-6: To a solution of (tert-butyloxycarbonyl)-L-homoserine benzyl ester (2.3 g, 7.44 mmol, 1.0 eq.) in tetrahydrofuran (30 ml) was added Dess-Martin reagent (4.7 g, 11.17 mmol, 1.5 eq.) at 0°C. The mixture was stirred at room temperature for 2 hours. The mixture was quenched with saturated sodium thiosulfate solution and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated to give the yellow oily product 20a-6 (3.5 g, crude product). LCMS (ESI): m / z=308 [M+H] + .
[0516] Preparation of compound 20a-7: A methanol solution (50 ml) of compound 20a-5 (3.65 g, 5.72 mmol, 1.0 eq), compound 20a-6 (1.8 g, 6.01 mmol, 1.05 eq), and acetic acid (343 mg, 5.72 mmol, 1.0 eq) was stirred at room temperature for 30 minutes. Sodium cyanoborohydride was added at 0°C. The mixture was stirred at room temperature for 1.5 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic phase was washed with saturated sodium carbonate solution and brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane to dichloromethane / methanol = 100 / 1 to 30 / 1) to give a white solid product 20a-7 (2.65 g, yield: 49.9%). LCMS (ESI): m / z = 930 [M+H] + .
[0517] Preparation of compound 20a-8: Compound 20a-7 (3 g, 3.23 mmol, 1.0 eq), 3-(tert-butyloxycarbonyl)amino)propionic acid (611 mg, 3.23 mmol, 1.0 eq), diisopropylethylamine (835 mg, 6.46 mmol, 2.0 eq) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.5 mg, 3.88 mmol, 1.2 eq) were added to dichloromethane (36 ml,), and the mixture was stirred at room temperature for 1 hour. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 100 / 1 to 20 / 1, 1% triethylamine was added) to give white solid compound 20a-8 (1.5 g, yield: 42.1%). LCMS (ESI): m / z = 1101 [M+H] + .
[0518] Preparation of compound 20a-9: Compound 20a-8 (1.5 g, 1.36 mmol, 1.0 eq) was added to 20 ml of 4M hydrogen chloride-dioxane solution. The mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to obtain a yellow solid product 20a-9 (1.1 g, crude product). LCMS (ESI): m / z=700 [M+H] + .
[0519] Preparation of compound 20a-10: Compound 20a-9 (1.1 g, 1.27 mmol, 1.0 eq), compound 1a-12 (2.3 g, 5.21 mmol, 4.1 eq), diisopropylethylamine (2 g, 15.24 mmol, 12.0 eq) and 2-(7-azobenzotriazole)-N, N, N', N'-tetramethyluronium hexafluorophosphate (2 g, 5.33 mmol, 4.2 eq) were added to 15 ml of acetonitrile, and the mixture was stirred at room temperature for 1 hour. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 100 / 1 to 10 / 1, triethylamine was added) to give a white solid compound DL20-8 (1.8 g, yield: 58.6%). LCMS (ESI): m / z=1209 [M / 2+H] + .
[0520] Preparation of compound 20a-11: Compound 20a-10 (800 mg, 0.331 mmol, 1.0 eq) was dissolved in 8 ml of ethanol, and trifluoroacetic acid (38 mg, 0.331 mmol, 1.0 eq) and 80 mg of 10% palladium hydroxide / carbon were added. The mixture was stirred at room temperature for two days under a hydrogen atmosphere. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a white solid compound 20a-11 (890 mg, crude product). LCMS (ESI): m / z=1097 [M / 2+H] + .
[0521] Preparation of compound 20a-12: Compound 20a-11 (760 mg, 0.346 mmol, 1.0 eq), diisopropylethylamine (134 mg, 1.038 mmol, 3.0 eq) and compound 2b-10 (97 mg, 0.381 mmol, 1.1 eq) were added to 10 ml of acetonitrile, and the mixture was stirred at room temperature for 1.5 hours. Diisopropylethylamine (134 mg, 1.038 mmol, 3.0 eq), 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (171 mg, 0.415 mmol, 1.2 eq) and intermediate M (249 mg, 0.415 mmol, 1.2 eq) were added, and the mixture was stirred at room temperature for 1 hour. The mixture was decompressed to remove the solvent. The residue was purified by preparative liquid chromatography (eluent: pH 7.0 potassium dihydrogen phosphate-potassium hydroxide buffer solution / acetonitrile) to give a yellow solid compound DL20-10 (272 mg, yield: 27.2%). LCMS (ESI): m / z=1308 [(M-302) / 2+H] + .
[0522] Preparation of compound 20a-13: Compound 20a-12 (172 mg, 0.0589 mmol, 1.0 eq), triethylamine (71 mg, 0.707 mmol, 12.0 eq), succinic anhydride (35 mg, 0.354 mmol, 6.0 eq) and p-dimethylaminopyridine (1 mg, 0.00589 mmol, 0.1 eq) were added to 1 ml of dichloromethane, and the mixture was stirred at room temperature overnight. The mixture was diluted with dichloromethane, washed with 10% sodium bicarbonate solution and saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give yellow solid compound 20a-13 (167 mg, crude product). LCMS (ESI): m / z=1358[(M-302) / 2+H]+.
[0523] Preparation of compound DL20-CPG: Compound 20a-13 (167 mg, 0.0554 mmol, 1.0 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (29 mg, 0.0775 mmol, 1.2 eq), 1-hydroxybenzotriazole (12 mg, 0.0886 mmol, 1.6 eq) and diisopropylethylamine (29 mg, 0.222 mmol, 4.0 eq) were added to 2 ml of dimethylformamide, and the mixture was stirred at room temperature for 5 minutes. 501 mg of CPG-NH2 was added, and the mixture was shaken at room temperature overnight. The mixture was filtered, the solid phase was washed with dichloromethane and acetonitrile, and the solid phase was dried under reduced pressure. 6 ml of pyridine and 2 ml of acetic anhydride were added, and the mixture was shaken for 3 hours. The solid phase was filtered, washed with dichloromethane and acetonitrile, and dried under reduced pressure to obtain a yellow solid compound DL20-CPG (532 mg, loading: 28.6 μmol / g).
[0524] Example 23 Preparation of Q20-CPG
[0525]
[0526] Preparation of compound 8a-2: A mixture of compound 8a-1 (2.72 g, 18.99 mmol, 1.0 eq), 4-piperidinyl carboxylate (2.72 g, 18.99 mmol, 1.0 eq), N, N-diisopropylethylamine (4.90 g, 37.98 mmol, 2.0 eq) and 2-(7-azabenzotriazole)-N, N, N', N'-tetramethyluronium hexafluorophosphate (8.47 g, 22.28 mmol, 1.2 eq) in dichloromethane (50 ml) was stirred at room temperature for 30 minutes. The mixture was concentrated under reduced pressure, the residue was diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated to give a yellow oily product 8a-2 (12.7 g, crude product). LCMS (ESI): m / z=389 [M+H] +.
[0527] Preparation of compound 8a-3: A solution of compound 8a-2 (crude product) in hydrogen chloride-dioxane (40 ml) was stirred at room temperature for 1 hour. The solvent was removed under vacuum. The residue was used directly in the next step without purification (crude product). LCMS (ESI): m / z=289 [M+H] + .
[0528] Preparation of compound 8a-4: A mixture of compound 8a-3 (crude), hept-6-ynoic acid (2.35 g, 18.69 mmol, 1.0 eq), N,N-diisopropylethylamine (7.23 g, 56.06 mmol, 3.0 eq) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (8.52 g, 22.42 mmol, 1.2 eq) in dichloromethane (50 ml) was stirred at room temperature for 30 minutes. The mixture was concentrated under reduced pressure, and the residue was diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate to dichloromethane / methanol = 20 / 1) to give a yellow oily product 8a-4 (8.19 g, crude). LCMS (ESI): m / z=397 [M+H] + .
[0529] Preparation of compound 8a-5: A mixture of compound 8a-4 (8.19 g, 18.69 mmol, 1.0 eq) and sodium hydroxide (1.24 g, 30.94 mmol, 1.5 eq) in tetrahydrofuran / methanol / water (20 ml / 10 ml / 10 ml) was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure, diluted with water, adjusted to pH=3 with dilute hydrochloric acid and extracted with dichloromethane. The organic phase was dried over anhydrous sodium sulfate and concentrated to give a yellow oily product 8a-5 (6.0 g, crude product). LCMS (ESI): m / z=383 [M+H] + .
[0530] Preparation of compound 8a-6: A mixture of compound 8a-5 (1.1 g, 2.87 mmol, 1.0 eq), compound 2a-6 (1.22 g, 2.15 mmol, 0.75 eq), N, N-diisopropylethylamine (1.11 g, 8.62 mmol, 3.0 eq) and 2-(7-azabenzotriazole)-N, N, N', N'-tetramethyluronium hexafluorophosphate (1.31 g, 3.45 mmol, 1.2 eq) in N, N-dimethylformamide (10 ml) was stirred at room temperature for 1 hour. The mixture was purified by preparative high performance liquid chromatography (A: pH = 7 phosphate buffer, B: acetonitrile, acetonitrile concentration 30%-90% within 30 minutes) to give a white solid product 8a-6 (320 mg, yield: 16%). LCMS(ESI): m / z=627[(M-302)+H] + .
[0531] Preparation of compound 8a-7: A mixture of compound 8a-6 (320 mg, 0.34 mmol, 1.0 eq), succinic anhydride (207 mg, 2.07 mmol, 6.0 eq), triethylamine (418 mg, 4.14 mmol, 12.0 eq) and 4-dimethylaminopyridine (5 mg, 0.034 mmol, 0.1 eq) in dichloromethane (5 ml) was stirred overnight at room temperature. The mixture was diluted with dichloromethane and washed with 10% sodium bicarbonate solution and saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo to give a yellow solid product 8a-7 (380 mg, crude product). LCMS (ES I): m / z=727[(M-302)+H] + . 1 HNMR(500MHz,MeOD)δ7.42–7.12(m,9H),6.93–6.71(m,4H),5.55–5.28(m,1H),4.40(dd,J=44.2,7.2 Hz,2H),4.32–4.16(m,3H),3.91–3.82(m,2H),3.77(s,6H),3.72–3.60(m,8H),3.54(td,J=13.4,6.2 Hz,6H),3.35(dd,J=14.8,9.4Hz,4H),3.18–3.05(m,6H),3.02–2.82(m,1H),2.64–2.41(m,6H),2.39 –2.24(m,1H),2.17(dtd,J=17.2,12.8,5.6Hz,5H),1.81–1.60(m,5H),1.51(dt,J=14.4,7.0Hz,3H).
[0532] Preparation of compound Q20-CPG: To a solution of compound 8a-7 (380 mg, 0.37 mmol, 1.0 eq) in N,N-dimethylformamide (10 ml) were added 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (169 mg, 0.44 mmol, 1.2 eq), 1-hydroxybenzotriazole (70 mg, 0.52 mmol, 1.4 eq) and N,N-diisopropylethylamine (191 mg, 1.48 mmol, 4.0 eq) and the mixture was shaken at room temperature for 5 minutes. CPG-NH2 (1.9 g) was then added to the reaction mixture and shaken overnight at room temperature. The mixture was filtered and the filter cake was washed with dichloromethane, acetonitrile, dichloromethane and dried under vacuum for 1 hour. Pyridine / acetic anhydride (7.5 ml / 2.5 ml) was added to the residue and shaken at room temperature for 3 hours. The mixture was filtered, and the filter cake was washed with dichloromethane, acetonitrile, and dichloromethane, and dried under vacuum for 1 hour to obtain a light yellow solid product Q20-CPG (2.08 g, loading: 101 μmol / g).
[0533] Example 24 Synthesis of dual-targeting siRNA
[0534]
[0535] 1. Synthesis of two siRNA sense strands for dual-targeting siRNA conjugation
[0536] First, the solid phase oligonucleotide synthesis method in Example 1 was used to replace the solid phase carrier with DL07-CPG and Q20-CPG to synthesize DL07-siRNA-1-SS containing an azide group and Q20-siRNA-2-SS containing an alkyne group, respectively; and the corresponding antisense strand was synthesized using universal CPG.
[0537] 2. Synthesis of Dual-targeting siRNA-SS Chains
[0538] A certain amount of DL07-siRNA-1-SS and Q20-siRNA-2-SS were taken respectively, dissolved in DEPC water, mixed in an equivalent ratio of 1:1.5, and CuSO4·5H2O (45 equiv.), THPTA (225 equiv.), NaVc (205 equiv.), MgCl2 aqueous solution (100 mM, 50 equiv.), TEAA Buffer (2 M, 1000 equiv.) and DMSO (1 / 2 the volume of DEPC water) were added, and the reaction was allowed to react at room temperature overnight. After the reaction was complete as monitored by LC-MS, three times the volume of anhydrous ethanol and 1 / 3 volume of 3M NaCl solution were added to the reaction solution, and the mixture was fully shaken and placed at -20°C for about 30 min; centrifuged at 15,000 rpm at 4°C for 3 min, the solution was removed by aspiration, and DEPC water was added to dissolve the mixture. After the concentration was detected, the mixture was purified by HPLC to obtain a dual-targeted siRNA-SS chain (siRNA-1-SS-DL07-Q20-siRNA-2-SS).
[0539] 3. Synthesis of Dual-targeting siRNA
[0540] A certain amount of dual-targeting siRNA-SS (siRNA-1-SS-DL07-Q20-siRNA-2-SS) chain was dissolved in DEPC water, and equivalent amounts of two antisense chains siRNA-1-AS and siRNA-2-AS were added thereto; heated at 95°C for 5 minutes, and then naturally cooled to room temperature to obtain dual-targeting siRNA (siRNA-1-DL07-Q20-siRNA-2).
[0541] When other linkers and delivery systems are used, the synthesis of dual-targeting siRNA can refer to this example.
[0542] Table 45: Dual-target sequence and delivery system structure information
[0543]
[0544]
[0545]
[0546]
[0547]
[0548]
[0549]
[0550]
[0551]
[0552]
[0553]
[0554] The structures of the dual-targeting siRNA-linked ligands listed in the above table are shown below:
[0555]
[0556] Example 25 Evaluation of the effects of dual-targeting siRNA delivered with different structures on the expression of AGT and PCSK9 in primary hepatocytes of AAV8-hAGT / hPCSK9 mice
[0557] Table 46: Experimental results of different delivery methods of dual-targeting siRNA at different concentrations in AAV8-hAGT / hPCSK9 mouse primary hepatocytes
[0558]
[0559]
[0560] The experiment showed that the activity of all dual-targeted siRNAs was much higher than that of two independent positive references mixed in a mixed manner. At the same time, we found that different delivery systems had different effects on the activity of the two targets. Among them, the siRNAs delivered by DL07-Q20, DL09-Q20 and DL20-Q20 had the best activity, which was much higher than the positive reference 1000PM mixed with 11000PM. Next, we tested the IC50 value of the active dual-target structure DT03081 for knocking down the two targets in AAV8-hAGT / hPCSK9 mouse primary hepatocytes.
[0561] Table 47: IC50 experimental results of DT03081 in AAV8-hAGT / hPCSK9 mouse primary hepatocytes
[0562]
[0563] As shown in Table 47, the IC50 of DT03081 for the inhibition of AGT and PCSK9 targets reached about 44 pM, which is extremely active. At the same time, the inhibitory activity of the two targets is comparable, which means that DT03081 can synchronously and persistently inhibit the expression of the two targets in vivo.
[0564] Some other combinations of AGT and PCSK9 target preferred sequences were evaluated for activity in vitro using the same delivery system, and the results are as follows.
[0565] Table 48: Experimental results of different delivery methods of dual-targeting siRNA at different concentrations in AAV8-hAGT / hPCSK9 mouse primary hepatocytes
[0566]
[0567]
[0568] It can be seen from the data that the dual-targeting siRNA activity of multiple preferred sequence combinations is better than the positive reference 1000PM mixed 11000PM
[0569] Example 26 Evaluation of the effects of different dual-target sequences on hAGT and hPCSK9 protein expression levels in mice expressing both hAGT and hPCSK9
[0570] Experimental methods:
[0571] 1. Adenovirus integration of hAGT / hPCSK9
[0572] By 1.5x10 11 Titer ultra-purified recombinant AAV8-hAGT and 1.5x10 11 The mice were co-infected with titered ultra-purified recombinant AAV8-hPCSK9 viral particles to obtain transgenic mice stably expressing hAGT / hPCSK9.
[0573] 2. Experimental grouping and drug administration
[0574] 14 days after the mice were injected with the virus, blood was collected from the submandibular vein, left to stand at room temperature for 30 minutes, centrifuged at 1000×g for 10 minutes, and the supernatant serum was taken and stored in a -80 degree refrigerator. The serum samples were diluted 1000 times, and the expression of hAGT and hPCSK9 in mouse serum was detected by Human Angiotensinogen / AGT / SerpinA8 ELISA Kit (Lianke Bio, Cat. No.: EK1202–96) and Human PCSK9 ELISA Kit proteintech (Cat No: KE00278), respectively. Based on the expression of hAGT and hPCSK9, the mice were divided into groups, 4 in each group. siRNA was dissolved in physiological saline, and the concentration was adjusted to 10uM. The mice were subcutaneously injected with siRNA solution at a dose of 60nmol / kg or 180nmol / kg.
[0575] 3.ELISA test
[0576] After siRNA injection, a small amount of blood was collected from the submandibular vein every other week, left to stand at room temperature for 30 minutes, centrifuged at 1000×g for 10 minutes, and the supernatant serum was collected. After diluting 1000 times, the expression of hPCSK9 was detected by ELISA.
[0577] The experimental results are shown in Table 2. Figure 1
[0578] Table 49: Inhibitory effect of AGT / PCSK9 dual-targeting siRNA DT03081 on two targets in AAV8-hAGT / hPCSK9 mice at a dose of 60 nmol / kg
[0579]
[0580] From Table 49 and Figure 1 and Figure 2 We can see that at a dose of 60nmol / kg, DT03081 has a good knockdown effect on both AGT and PCSK9 targets in vivo, and is much better than the efficacy of Zilebesiran mixed with Inclisiran. And from the duration of the mixed administration of the two positive drugs, we can see that the inhibition rate of 1000PM is still about 50% on the 56th day, while the inhibition rate of 11000PM on PCSK9 has recovered to about 50% on the 27th day. The inhibition duration of the two sequences on the target is inconsistent. The inhibition level of DT03081 obtained by sequence optimization and delivery structure optimization in the two targets basically follows the same trend over time, so the administration time and frequency are more controllable clinically.
[0581] Table 50: Inhibitory effects of AGT / PCSK9 dual-targeting siRNA on two targets in AAV8-hAGT / hPCSK9 mice at different doses
[0582]
[0583] We further compared the activities of our preferred sequences after forming dual targets. From the data, we can see that the activities of DT03081, DT03082, DT03085 and DT03086 are comparable.
[0584] The activities of other preferred sequences combined into dual targets were also compared at a dose of 60 nmol / kg.
[0585] Experimental methods:
[0586] 1. Adenovirus integration of hAGT / hPCSK9
[0587] By 1.5x10 11The humanized PCSK9 mice were infected with ultra-purified recombinant AAV8-hAGT virus particles to obtain transgenic mice stably expressing hAGT / hPCSK9.
[0588] 2. Experimental grouping and drug administration
[0589] 14 days after the mice were injected with the virus, blood was collected from the submandibular vein, left to stand at room temperature for 30 minutes, centrifuged at 1000×g for 10 minutes, and the supernatant serum was taken and stored in a -80 degree refrigerator. The serum samples were diluted 1000 times, and the expression of hAGT and hPCSK9 in mouse serum was detected by Human Angiotensinogen / AGT / SerpinA8 ELISA Kit (Lianke Bio, Cat. No.: EK1202–96) and Human PCSK9 ELISA Kitproteintech (Cat No: KE00278), respectively. Based on the expression of hAGT and hPCSK9, the mice were divided into groups, 4 per group. siRNA was dissolved in saline, the concentration was adjusted to 10uM, and the mice were subcutaneously injected with siRNA solution at a dose of 60nmol / kg.
[0590] 3.ELISA test
[0591] After siRNA injection, a small amount of blood was collected from the submandibular vein every other week, left to stand at room temperature for 30 minutes, centrifuged at 1000×g for 10 minutes, and the supernatant serum was collected. After diluting 1000 times, the expression of hPCSK9 was detected by ELISA.
[0592] The experimental results are shown in the table.
[0593] Table 51: Inhibitory effects of AGT / PCSK9 dual-targeting siRNA on two targets in humanized PCSK9 mice infected with AAV8 hAGT virus at a dose of 60 nmol / kg
[0594]
[0595]
[0596] As can be seen from the data, the activities of multiple dual-targeting siRNAs are comparable to or slightly better than DT03081. Example 27 Evaluation of the effects of different dual-target sequences on the expression of hAGT and hANGPTL3 in the liver in mice expressing both hAGT and hANGPTL3
[0597] Experimental methods:
[0598] 1. Adenovirus Integration of hAGT and hANGPTL3
[0599] By 1x10 11Titer ultra-purified recombinant AAV8 hAGT and 1x10 11 The mice were infected with ultra-purified recombinant AAV8 hANGPTL3 virus particles to obtain transgenic mice that stably express both hAGT and hANGPTL3. 100ul of virus was added to 5.9mL PBS, and 200ul of virus dilution was injected intravenously into each mouse.
[0600] 2. Drug administration
[0601] 14 days after the mice were injected with the virus, the mice were divided into groups, with 4 mice in each group. siRNA was dissolved in physiological saline and injected subcutaneously at a dose of 60 nmol / kg.
[0602] 3. Liver sampling and testing
[0603] The liver was harvested at different time points after siRNA injection, and RNA in the liver tissue was extracted by TRI REAGENT (MRC, Catalog No.: TR118), and the extracted RNA was reverse transcribed into cDNA using PrimeScript RT regent Kit (Takara, Catalog No.: RR047A). The prepared QPCR system was added to a 96-well PCR plate, sealed with a plate sealer, and QPCR was performed on the StepOnePlus real-time PCR system (appliedbiosystems) to detect the expression levels of hAGT and hANGPTL3.
[0604] Table 52: Inhibitory effect of AGT / ANGPTL3 dual-targeting siRNA on two targets in AAV8-hAGT / hANGPTL3 mice at a dose of 60 nmol / kg
[0605]
[0606] The AGT target preferred sequences 1167.25-19, 1167.27-21, 1165.5-16, 1161.7-17 were combined with the ANGPTL3 target preferred sequences 7061.18-14, 7061.4-16 to obtain AGT / ANGPTL3 dual-targeting siRNA DT02042, DT02043, DT02047, DT02058 and DT02059, which were evaluated for activity in vivo together with the positive reference sequence. As can be seen from Table 52, the activity of different sequence combinations varies greatly. The sequence with the best activity is DT02043, and its two target activities are much better than the positive reference 1000PM mixed ARO-ANG3, while the activity of the dual-targeting siRNA DT02042 with the worst activity is worse than the positive reference. Further comparison of DT02043 and DT02047 showed that although the ANGPTL3-targeting parts of the two dual-target siRNAs both used the 7061.4-16 sequence, the activities of targeting ANGPTL3 were very different due to the different sequences of the linked AGT-targeting parts.
[0607] Example 28 Evaluation of the effects of different dual-target sequences on the expression levels of hANGPTL3 and hPCSK9 in mice expressing both hANGPTL3 and hPCSK9
[0608] Experimental methods:
[0609] 1. Adenovirus integration of hANGPTL3 / hPCSK9
[0610] By 1.5x10 11 Titer ultra-purified recombinant AAV8-hANGPTL3 and 1.5x10 11 The mice were co-infected with titered ultra-purified recombinant AAV8-hPCSK9 viral particles to obtain transgenic mice stably expressing hANGPTL3 / hPCSK9.
[0611] 2. Experimental grouping and drug administration
[0612] 14 days after the mice were injected with the virus, blood was collected from the submandibular vein, left to stand at room temperature for 30 minutes, centrifuged at 1000×g for 10 minutes, and the supernatant serum was taken and stored in a -80 degree refrigerator. The serum sample was diluted 1000 times, and the expression of hPCSK9 in mouse serum was detected by Human PCSK9 ELISA Kitproteintech (Cat No: KE00278). Based on the expression level of hPCSK9, the mice were evenly divided into groups, with 4 mice in each group. siRNA was dissolved in physiological saline, the concentration was adjusted to 10uM, and the mice were subcutaneously injected with siRNA solution at a dose of 60nmol / kg.
[0613] 3.ELISA test
[0614] After siRNA injection, a small amount of blood was collected from the submandibular vein every other week, left to stand at room temperature for 30 minutes, centrifuged at 1000×g for 10 minutes, and the supernatant serum was collected. After diluting 1000 times, the expression of hPCSK9 was detected by ELISA.
[0615] 4. Liver sampling and testing
[0616] The liver was harvested at different time points after siRNA injection, and RNA in the liver tissue was extracted by TRI REAGENT (MRC, Catalog No.: TR118), and the extracted RNA was reverse transcribed into cDNA using PrimeScript RT regent Kit (Takara, Catalog No.: RR047A). The prepared QPCR system was added to a 96-well PCR plate, sealed with a plate sealer, and QPCR was performed on the StepOnePlus real-time PCR system (appliedbiosystems) to detect the expression levels of hPCSK9 and hANGPTL3.
[0617] Table 53: Inhibitory effects of PCSK9 / ANGPTL3 dual-targeting siRNA on two targets in AAV8-hPCSK9 / hANGPTL3 mice at a dose of 60 nmol / kg
[0618]
[0619] The ANGPTL3 targeting sequence 7061 preferred siRNA 7061.4-16, 7061.18-14 were combined with the PCSK9 targeting sequence 11040.10-23, 11002.17-21 to obtain ANGPTL3 / PCSK9 dual-targeting siRNA DT09001, DT09003 and DT09005, and the activity was evaluated in AAV8-hANGPTL3 / hPCSK9 mice. Blood and liver were collected at different time points, and the expression levels of PCSK9 and ANGPTL3 were detected by ELISA and QPCR, respectively. From the data, it can be seen that DT09001 and DT09005 have the best knockdown activity for the two targets. In this experiment, we also found that even though the dual-target siRNA DT09003 and DT09005 both use the 11002.17-21 sequence to target PCSK9, the activity of targeting PCSK9 is very different due to the different sequences of the linked ANGPTL3 targeting.
[0620] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A dual-targeting siRNA agent, characterized in that: The dual-targeting siRNA agent comprises two different siRNAs or pharmaceutically acceptable salts thereof targeting two different genes, wherein the two different siRNAs or their salts are connected to a ligand for delivering nucleic acid to form a whole, each of the siRNAs is a dsRNA consisting of a positive strand and an antisense strand, and the two different genes are selected from two of angiotensinogen (AGT), proprotein convertase subtilisin / kexin type 9 (PCSK9) and angiopoietin-like 3 (ANGPTL3); The base composition of the siRNA targeting the angiotensinogen gene is selected from any of the following dsRNA sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide: A) 1167f: the sense strand thereof is shown in SEQ ID NO: 59, and the antisense strand thereof is shown in SEQ ID NO: 60; B) 1167b: the sense strand thereof is shown in SEQ ID NO: 51, and the antisense strand thereof is shown in SEQ ID NO: 52; C) 1165d: the sense strand thereof is shown in SEQ ID NO: 39, and the antisense strand thereof is shown in SEQ ID NO: 40; D) 1165f: the sense strand thereof is shown in SEQ ID NO: 43, and the antisense strand thereof is shown in SEQ ID NO: 44; The base composition of the siRNA targeting the proprotein convertase subtilisin protease 9 gene is selected from any of the following dsRNA sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide: E) 11040a: the sense strand thereof is shown in SEQ ID NO: 375, and the antisense strand thereof is shown in SEQ ID NO: 376; F) 11002d: the sense strand thereof is shown in SEQ ID NO: 259, and the antisense strand thereof is shown in SEQ ID NO: 260; G) 11002a: the sense strand thereof is shown in SEQ ID NO: 253, and the antisense strand thereof is shown in SEQ ID NO: 254; The base composition of the siRNA targeting angiopoietin-like protein 3 is selected from any of the following dsRNA sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide: H) 7061f: the sense strand thereof is as shown in SEQ ID NO: 579, and the antisense strand thereof is as shown in SEQ ID NO: 580; I) 7061b, the sense strand of which is shown in SEQ ID NO: 571, and the antisense strand of which is shown in SEQ ID NO:
572.
2. The dual-targeting siRNA agent according to claim 1, characterized in that The two genes targeted are AGT and any one selected from PCSK9 and ANGPTL3, preferably AGT and PCSK9.
3. The dual-targeting siRNA agent according to claim 1, characterized in that The nucleotides of the sense strand and the antisense strand are modified, the sense strand comprises no more than 3, 2, 1 or 0 unmodified nucleotides, the modified nucleotides in the sense strand comprise 2'-O-methyl modified nucleotides, 2'-deoxy nucleotides, 2'-fluorine modified nucleotides, reverse abasic residues, and the 5'-end and 3'-end of the sense strand contain 0, or 1, or 2, or 3 phosphorothioate bonds; and the antisense strand comprises no more than 3, 2, 1 or 0 unmodified Nucleotides, the modified nucleotides in the antisense chain include 2'-O-methyl modified nucleotides, 2'-deoxynucleotides, 2'-fluorine modified nucleotides, VPU (2'-O-methyluridine-5'-(E)-vinyl phosphoric acid-3'-phosphate), VPU-S (2'-S-methyluridine-5'-(E)-vinyl phosphoric acid-3'-phosphate) or other VPU derivatives, and the 5'-end and 3'-end of the antisense chain each contain 1-3 phosphorothioate bonds.
4. The dual-targeting siRNA agent according to claim 3, characterized in that The siRNA targeting the angiotensinogen gene is modified and selected from one of the following sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide: a) 1167.25-19: its 5'-3' sense strand is Invab*mU*mGmAmCmCmAfGfCfUfUmGfUmUmUmGmUmGmAmAInvab, and its 5'-3' antisense strand is VPU-S*fU*mCmAmCmAmAmAmCmAmAdGmCfUmGfGmUmCmG*mG*mG; b) 1167.27-21: its 5'-3' sense strand is Invab*mG*mCmCmGmAmCmCmAfGfCfUfUmGfUmUmUmGmUmGmAmAInvab, and its 5'-3' antisense strand is VPU-S*fU*mCmAmCmAmAmAmCmAmAdGmCfUmGfGmUmCmG*mG*mC; c) 1165.5-14: its 5'-3' sense strand is Invab*mG*mAmGmAmAmCfCfAfGfUmGfUmUmUmAmGmCmGmAInvab, and its 5'-3' antisense strand is VPU-S*fC*mGmCmUmAmAmAmCmAmCdTmGfGmUfUmCmUmU*mG*mG; d) 1165.5-16: its 5'-3' sense strand is Invab*mC*mCmAmAmGmAmAmCfCfAfGfUmGfUmUmUmAmGmCmGmAInvab, and its 5'-3' antisense strand is VPU-S*fC*mGmCmUmAmAmAmCmAmCdTmGfGmUfUmCmUmU*mG*mG; Among them, VPU-S is 2'-S-methyluridine-5'-(E)-vinylphospho-3'-phosphate, mA is 2'-O-methyladenosine-3'-phosphate, mU is 2'-O-methyluridine-3'-phosphate, mC is 2'-O-methylcytidine-3'-phosphate, mG is 2'-O-methylguanosine-3'-phosphate, fA is 2'-fluoroadenosine-3'-phosphate, and fU is 2'- fluorouridine-3'-phosphate, fC is 2'-fluorocytidine-3'-phosphate, fG is 2'-fluoroguanosine-3'-phosphate, dA is 2'-deoxyadenosine-3'-phosphate, dT is 2'-deoxythymidine-3'-phosphate, dC is 2'-deoxycytidine-3'-phosphate, dG is 2'-deoxyguanosine-3'-phosphate, Invab is an inverted abasic residue, and * is a phosphorothioate bond.
5. The dual-targeting siRNA agent according to claim 3 or 4, characterized in that: The siRNA targeting the proprotein convertase subtilisin 9 gene is modified and selected from one of the following sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide: e) 11040.10-23, the 5'-3' sense strand of which is Invab*mC*mUmUmAmUmUmCmUfGfGfGfUmUfUmUmGmUmAmGmCmAInvab, and the 5'-3' antisense strand of which is VPU-S*fG*mCmUmAmCmAmAmAmAmCdCmCfAmGfAmAmUmA*mA*mG; f) 11002.17-21, whose 5'-3' sense strand is Invab*mG*mCmAmGmCmCfAfAfCfUmUfUmUmCmUmAmGmAmAInvab, and whose 5'-3' antisense strand is VPU-S*fU*mCmUmAmGmAmAmAmAmGdTmUfGmGfCmUmGmU*mG*mG; g) 11002.10-23, whose 5'-3' sense strand is Invab*mC*mUmAmCmAmGmCmCfAfAfCfUmUfUmUmCmUmAmGmAmAInvab, and whose 5'-3' antisense strand is VPU-S*fU*mCmUmAmGmAmAmAmAmGdTmUfGmGfCmUmGmU*mA*mG; Among them, VPU-S is 2'-S-methyluridine-5'-(E)-vinylphospho-3'-phosphate, mA is 2'-O-methyladenosine-3'-phosphate, mU is 2'-O-methyluridine-3'-phosphate, mC is 2'-O-methylcytidine-3'-phosphate, mG is 2'-O-methylguanosine-3'-phosphate, fA is 2'-fluoroadenosine-3'-phosphate, and fU is 2'- fluorouridine-3'-phosphate, fC is 2'-fluorocytidine-3'-phosphate, fG is 2'-fluoroguanosine-3'-phosphate, dA is 2'-deoxyadenosine-3'-phosphate, dT is 2'-deoxythymidine-3'-phosphate, dC is 2'-deoxycytidine-3'-phosphate, dG is 2'-deoxyguanosine-3'-phosphate, Invab is an inverted abasic residue, and * is a phosphorothioate bond.
6. The dual-targeting siRNA agent according to claim 3 or 4, characterized in that: The siRNA targeting the angiopoietin-like protein 3 gene is modified, and the siRNA is selected from one of the following sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide: h) 7061.18-14: its 5'-3' sense strand is Invab*mU*mAmCmUmUmGfAfAfCfUmCfAmAmCmUmCmAmAmAInvab, and its 5'-3' antisense strand is VPU-S*fU*mUmGmAmGmUmUmGmAmGdTmUfCmAfAmGmUmG*mG*mG; i) 7061.4-16: its 5'-3' sense strand is Invab*mG*mCmCmAmCmUmUmGfAfAfCfUmCfAmAmCmUmCmAmAmAInvab, and its 5'-3' antisense strand is VPU-S*fU*mUmGmAmGmUmUmGmAmGdTmUfCmAfAmGmUmG*mG*mC; Among them, VPU-S is 2'-S-methyluridine-5'-(E)-vinylphospho-3'-phosphate, mA is 2'-O-methyladenosine-3'-phosphate, mU is 2'-O-methyluridine-3'-phosphate, mC is 2'-O-methylcytidine-3'-phosphate, mG is 2'-O-methylguanosine-3'-phosphate, fA is 2'-fluoroadenosine-3'-phosphate, and fU is 2'- fluorouridine-3'-phosphate, fC is 2'-fluorocytidine-3'-phosphate, fG is 2'-fluoroguanosine-3'-phosphate, dA is 2'-deoxyadenosine-3'-phosphate, dT is 2'-deoxythymidine-3'-phosphate, dC is 2'-deoxycytidine-3'-phosphate, dG is 2'-deoxyguanosine-3'-phosphate, Invab is an inverted abasic residue, and * is a phosphorothioate bond.
7. The dual-targeting siRNA agent according to claim 5, characterized in that: When targeting AGT and PCSK9 genes, each siRNA of the dual-targeted siRNA agent is selected from any one of DT03081, DT03086, DT03103, DT03099, DT03085, DT03101, DT03082, DT03097, DT03100 or DT03102 in Table 45.
8. The dual-targeting siRNA agent according to claim 6, characterized in that When targeting AGT and ANGPTL3 genes, each siRNA of the dual-targeting siRNA agent is selected from any one of the dual-targeting siRNAs in DT02043 or DT02047 in Table 45.
9. The dual-targeting siRNA agent according to claim 3, characterized in that: When targeting ANGPTL3 and PCSK9 genes, each siRNA of the dual-targeting siRNA agent is selected from any one of the dual-targeting siRNAs of DT09001, DT09003 and DT09005 in Table 45.
10. The dual-targeting siRNA agent according to any one of claims 1 to 4, characterized in that: The pharmaceutically acceptable salt is a sodium salt or a potassium salt.
11. The dual-targeting siRNA agent according to any one of claims 1 to 4, characterized in that: The ligand is N-acetylgalactosamine (GalNAc) or a derivative thereof.
12. The dual-targeting siRNA agent according to claim 11, characterized in that: The N-acetylgalactosamine derivative is connected to the 3' ends of the sense strands of the two siRNAs respectively through chemical bonds, preferably, the chemical bonds are phosphate bonds or phosphorothioate bonds.
13. The dual-targeting siRNA agent according to claim 12, characterized in that: The N-acetylgalactosamine derivative has the following structure, and is connected to the 3' end of the sense strand of each siRNA in the following manner: in It represents siRNA targeting a modified sequence of the AGT gene, PCSK9 gene or ANGPTL3 gene.
14. Use of the dual-targeted siRNA agent according to any one of claims 1 to 13 in the preparation of a product for simultaneously inhibiting the expression of any two target genes AGT, PCSK9 and ANGPTL3 in cells, preferably, the product is a biological preparation or a pharmaceutical preparation.
15. A biological agent or pharmaceutical agent for simultaneously inhibiting the expression of any combination of two target genes of AGT, PCSK9 and ANGPTL3, characterized in that: The active ingredient thereof comprises the dual-targeting siRNA agent according to any one of claims 1 to 13.
16. Use of the dual-targeted siRNA agent according to any one of claims 1 to 13 in the preparation of a drug for preventing and / or treating diseases related to hypertension and / or lipid disorders, characterized in that: The hypertension is mediated by the AGT gene, and the lipid disorder-related disease is mediated by the PCSK9 gene or the ANGPTL3 gene.
17. The use according to claim 16, characterized in that: The hypertension is critical hypertension, essential hypertension, secondary hypertension, hypertensive crisis, hypertensive emergency state, isolated systolic and diastolic hypertension, pregnancy-related hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt's hypertension, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension and unstable hypertension or any other disease mediated by the AGT gene.
18. The use according to claim 16, characterized in that: The lipid disorder-related disease is mediated by the PCSK9 gene and is selected from hyperlipidemia, atherosclerosis, non-alcoholic fatty hepatitis, and non-alcoholic fatty liver disease.
19. The use according to claim 16, characterized in that: The lipid disorder-related disease is mediated by the ANGPTL3 gene and is selected from any one of hyperlipidemia, hypertriglyceridemia, lipid and / or cholesterol metabolism disorders, homozygous and heterozygous familial hypercholesterolemia, statin-resistant hypercholesterolemia, cardiometabolic disease, obesity, atherosclerosis, type II diabetes, cardiovascular disease, coronary artery disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, and pancreatitis caused by hypertriglyceridemia.
20. A method for simultaneously inhibiting the expression of any two target genes of AGT, PCSK9 and ANGPTL3 in cells in vivo or in vitro, characterized in that: The method comprises: (a) contacting in vivo or in vitro cells with the dual-targeting siRNA agent according to any one of claims 1 to 13 or the biological agent or pharmaceutical agent according to claim 15; and (b) maintaining the cells produced in step (a) for a time sufficient to obtain degradation of mRNA transcripts expressed by any two target genes among AGT, PCSK9 and ANGPTL3, thereby simultaneously inhibiting the expression of any two target genes among AGT, PCSK9 and ANGPTL3 in the cells.
21. A method for treating a disease associated with AGT and / or PCSK9 and / or ANGPTL3, characterized in that: The method comprises administering to the subject a therapeutically effective amount of the dual-targeting siRNA agent according to any one of claims 1 to 13 or the biological agent or pharmaceutical agent according to claim 15, thereby treating the subject.
22. An siRNA targeting AGT gene or a pharmaceutically acceptable salt thereof, characterized in that: Its sequence is selected from one of the following, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide: A) 1167f: the sense strand thereof is shown in SEQ ID NO: 59, and the antisense strand thereof is shown in SEQ ID NO: 60; B) 1167b: the sense strand thereof is shown in SEQ ID NO: 51, and the antisense strand thereof is shown in SEQ ID NO: 52; C) 1165d: the sense strand thereof is shown in SEQ ID NO: 39, and the antisense strand thereof is shown in SEQ ID NO: 40; D) 1165f, the sense strand of which is shown in SEQ ID NO:43, and the antisense strand of which is shown in SEQ ID NO:
44.
23. The siRNA targeting the AGT gene or a pharmaceutically acceptable salt thereof according to claim 22, wherein: The siRNA is modified and selected from one of the following sequences, or a sense strand or antisense strand sequence that differs therefrom by no more than 1 nucleotide: a) 1167.25-19: its 5'-3' sense strand is Invab*mU*mGmAmCmCmAfGfCfUfUmGfUmUmUmGmUmGmAmAInvab, and its 5'-3' antisense strand is VPU-S*fU*mCmAmCmAmAmAmCmAmAdGmCfUmGfGmUmCmG*mG*mG; b) 1167.27-21: its 5'-3' sense strand is Invab*mG*mCmCmGmAmCmCmAfGfCfUfUmGfUmUmUmGmUmGmAmAInvab, and its 5'-3' antisense strand is VPU-S*fU*mCmAmCmAmAmAmCmAmAdGmCfUmGfGmUmCmG*mG*mC; c) 1165.5-14: its 5'-3' sense strand is Invab*mG*mAmGmAmAmCfCfAfGfUmGfUmUmUmAmGmCmGmAInvab, and its 5'-3' antisense strand is VPU-S*fC*mGmCmUmAmAmAmCmAmCdTmGfGmUfUmCmUmU*mG*mG; d) 1165.5-16: its 5'-3' sense strand is I nvab*mC*mCmAmAmGmAmAmCfCfAfGfUmGfUmUmUmAmGmCmGmAI nvab, and its 5'-3' antisense strand is VPU-S*fC*mGmCmUmAmAmAmCmAmCdTmGfGmUfUmCmUmU*mG*mG; Among them, VPU-S is 2'-S-methyluridine-5'-(E)-vinylphospho-3'-phosphate, mA is 2'-O-methyladenosine-3'-phosphate, mU is 2'-O-methyluridine-3'-phosphate, mC is 2'-O-methylcytidine-3'-phosphate, mG is 2'-O-methylguanosine-3'-phosphate, fA is 2'-fluoroadenosine-3'-phosphate, and fU is 2'- fluorouridine-3'-phosphate, fC is 2'-fluorocytidine-3'-phosphate, fG is 2'-fluoroguanosine-3'-phosphate, dA is 2'-deoxyadenosine-3'-phosphate, dT is 2'-deoxythymidine-3'-phosphate, dC is 2'-deoxycytidine-3'-phosphate, dG is 2'-deoxyguanosine-3'-phosphate, Invab is an inverted abasic residue, and * is a phosphorothioate bond.
24. A siRNA targeting PCSK9 gene or a pharmaceutically acceptable salt thereof, characterized in that: The siRNA is selected from one of the following sequences, or a sense strand or antisense strand sequence that differs therefrom by no more than 1 nucleotide: E) 11040a: the sense strand thereof is shown in SEQ ID NO: 375, and the antisense strand thereof is shown in SEQ ID NO: 376; F) 11002d: the sense strand thereof is shown in SEQ ID NO: 259, and the antisense strand thereof is shown in SEQ ID NO: 260; G) 11002a: Its sense strand is shown in SEQ ID NO: 253, and its antisense strand is shown in SEQ ID NO:
254.
25. The siRNA targeting PCSK9 gene or a pharmaceutically acceptable salt thereof according to claim 24, characterized in that: The siRNA is modified and selected from one of the following sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide: e) 11040.10-23, the 5'-3' sense strand of which is Invab*mC*mUmUmAmUmUmCmUfGfGfGfUmUfUmUmGmUmAmGmCmAInvab, and the 5'-3' antisense strand of which is VPU-S*fG*mCmUmAmCmAmAmAmAmCdCmCfAmGfAmAmUmA*mA*mG; f) 11002.17-21, whose 5'-3' sense strand is Invab*mG*mCmAmGmCmCfAfAfCfUmUfUmUmCmUmAmGmAmAInvab, and whose 5'-3' antisense strand is VPU-S*fU*mCmUmAmGmAmAmAmAmGdTmUfGmGfCmUmGmU*mG*mG; g) 11002.10-23, whose 5'-3' sense strand is Invab*mC*mUmAmCmAmGmCmCfAfAfCfUmUfUmUmCmUmAmGmAmAInvab, and whose 5'-3' antisense strand is VPU-S*fU*mCmUmAmGmAmAmAmAmGdTmUfGmGfCmUmGmU*mA*mG; Among them, VPU-S is 2'-S-methyluridine-5'-(E)-vinylphospho-3'-phosphate, mA is 2'-O-methyladenosine-3'-phosphate, mU is 2'-O-methyluridine-3'-phosphate, mC is 2'-O-methylcytidine-3'-phosphate, mG is 2'-O-methylguanosine-3'-phosphate, fA is 2'-fluoroadenosine-3'-phosphate, and fU is 2'- fluorouridine-3'-phosphate, fC is 2'-fluorocytidine-3'-phosphate, fG is 2'-fluoroguanosine-3'-phosphate, dA is 2'-deoxyadenosine-3'-phosphate, dT is 2'-deoxythymidine-3'-phosphate, dC is 2'-deoxycytidine-3'-phosphate, dG is 2'-deoxyguanosine-3'-phosphate, Invab is an inverted abasic residue, and * is a phosphorothioate bond.
26. An siRNA targeting ANGPTL3 gene or a pharmaceutically acceptable salt thereof, characterized in that: The siRNA is modified and selected from one of the following sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide: H) 7061f: the sense strand thereof is shown in SEQ ID NO: 579, and the antisense strand thereof is shown in SEQ ID NO: 580; I) 7061b, the sense strand of which is shown in SEQ ID NO: 571, and the antisense strand of which is shown in SEQ ID NO:
572.
27. The siRNA targeting the ANGPTL3 gene or a pharmaceutically acceptable salt thereof according to claim 26, characterized in that: The siRNA is modified and selected from one of the following sequences, or a sequence that differs from its sense strand or antisense strand by no more than 1 nucleotide: h) 7061.18-14: its 5'-3' sense strand is Invab*mU*mAmCmUmUmGfAfAfCfUmCfAmAmCmUmCmAmAmAInvab, and its 5'-3' antisense strand is VPU-S*fU*mUmGmAmGmUmUmGmAmGdTmUfCmAfAmGmUmG*mG*mG; i) 7061.4-16: its 5'-3' sense strand is Invab*mG*mCmCmAmCmUmUmGfAfAfCfUmCfAmAmCmUmCmAmAmAInvab, and its 5'-3' antisense strand is VPU-S*fU*mUmGmAmGmUmUmGmAmGdTmUfCmAfAmGmUmG*mG*mC; Among them, VPU-S is 2'-S-methyluridine-5'-(E)-vinylphospho-3'-phosphate, mA is 2'-O-methyladenosine-3'-phosphate, mU is 2'-O-methyluridine-3'-phosphate, mC is 2'-O-methylcytidine-3'-phosphate, mG is 2'-O-methylguanosine-3'-phosphate, fA is 2'-fluoroadenosine-3'-phosphate, and fU is 2'- fluorouridine-3'-phosphate, fC is 2'-fluorocytidine-3'-phosphate, fG is 2'-fluoroguanosine-3'-phosphate, dA is 2'-deoxyadenosine-3'-phosphate, dT is 2'-deoxythymidine-3'-phosphate, dC is 2'-deoxycytidine-3'-phosphate, dG is 2'-deoxyguanosine-3'-phosphate, Invab is an inverted abasic residue, and * is a phosphorothioate bond.
28. An siRNA agent targeting AGT, characterized in that The siRNA agent is formed by linking the siRNA or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 23 with a ligand for delivering nucleic acid.
29. A siRNA agent targeting PCSK9, characterized in that The siRNA agent is formed by linking the siRNA or a pharmaceutically acceptable salt thereof according to any one of claims 24 to 25 with a ligand for delivering nucleic acid.
30. An siRNA agent targeting ANGPTL3, characterized in that The siRNA agent is formed by linking the siRNA or a pharmaceutically acceptable salt thereof according to any one of claims 26 to 27 with a ligand for delivering nucleic acid.
31. The siRNA agent according to any one of claims 28 to 30, characterized in that The ligand is N-acetylgalactosamine or its derivatives. Preferably, the structural formula of the ligand is as follows:
32. The siRNA agent according to claim 31, characterized in that The ligand is connected to the 3' end of the sense strand via a chemical bond, preferably, the chemical bond is a phosphate bond or a phosphorothioate bond, and the connection method is as follows:
Citation Information
Patent Citations
Angiotensinogen (agt) irna compositions and methods of use thereof
CN106574268A
Angiotensinogen (AGT) irna compositions and methods of use thereof
CN112313335A
Modified double stranded oligonucleotides
CN116761616A
ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US20210095290A1
Sirna inhibiting angptl3 gene expression, and use thereof
WO2022268054A1
Cited By
DsRNA agent for inhibiting expression of angiotensinogen as well as derivative and application of dsRNA agent
CN122609570A
Combinations of antisense agents, pharmaceutical compositions and methods of use
WO2026133250A1
Combinations of antisense agents, pharmaceutical compositions and methods of use
WO2026133251A1
Combinations of antisense agents, pharmaceutical compositions and methods of use
WO2026133253A1
Dsrna conjugate for simultaneously inhibiting expression of c3 and c5 genes and use of dsrna conjugate
WO2026145589A1
